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ABSTRACT
Introduction: Individuals with head and neck cancer (HNCa) face myriad biopsychosocial
challenges. Even after treatment completion, these challenges may continue to cause diminished
quality of life (QoL). Resilience may serve to minimize the impact of HNCa and, thus, maximize
QoL. The purpose of this study was to identify resilience in HNCa survivors and explore its
potential relationship with QoL.
Methods: Thirty-one HNCa survivors completed three validated, self-report questionnaires
pertaining to the collection of resilience and QoL data. Descriptive, correlational, and
observational analyses were performed.
Results: Resilience was identified in the HNCa survivors and a positive correlation was found
between resilience and QoL.
Conclusions: Data suggest that resilience may buffer the influence of HNCa on QoL. Screening
for low levels of resilience may facilitate the identification of those who are vulnerable to the
impact of HNCa. Interventions that foster resilience may serve to ameliorate the challenges of
HNCa and improve QoL.
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CHAPTER 1
Introduction and Review of Literature
Introduction
Everyone who is born holds dual citizenship, in the kingdom of the well and in the
kingdom of the sick. Although we all prefer to use only the good passport, sooner or later
each of us is obliged, at least for a spell, to identify ourselves as citizens of that other
place. (Sontag, 1978, p. 3)
The diagnosis of head and neck cancer (HNCa) acts as a vehicle through which an
individual is permitted to cross the border from the kingdom of the well to the kingdom of the
sick. Citizens of the kingdom of the sick are initiated by the disabling physical, psychological,
and social consequences of HNCa and its treatment. Owing to medical advancements in
oncological treatment, an increasing number of individuals residing in the kingdom of the sick
secondary to a diagnosis of HNCa are commonly issued a third passport. This additional passport
grants them citizenship to a new kingdom that Frank (1995) refers to as the “remission society”
(p. 8). For those who have completed treatment for HNCa, gaining citizenship to the remission
society implies that individuals are no longer sick, but simultaneously remain marked by their
past experience of sickness (Frank, 1995).
Unfortunately, citizenship in the remission society comes at a great cost. Despite
delivering a biological cure for cancer, advanced medical treatment often leaves members of the
remission society who are deemed “cancer free” at a great distance away from the kingdom of
the well. It follows that something must be done to provide HNCa survivors with the direction
they need to navigate the complex path back to the kingdom of the well. In essence, before
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survivors leave the kingdom of the sick, they should be equipped with a map to guide them
through the process of positive adaptation to their experience with HNCa. If a proactive stance is
adopted in oncological care to help those who will become cancer survivors rebound from their
time spent in the kingdom of the sick, individuals may find their way back to the kingdom of the
well more effectively. As part of this journey, resilience may serve as the proverbial map that
aids HNCa survivors’ navigation back to the kingdom of the well. Intrinsically, resilience may
enable HNCa survivors who are citizens of the remission society to bridge the potentially
expansive gap between Sontag’s two metaphoric kingdoms.
Regrettably, the distance between the kingdoms of the sick and well may become
expansive as a result of significant detriments to quality of life (QoL) secondary to HNCa and its
treatment. Poor QoL often denotes that a significant gap exists between an individual’s ideal
functional status and current level of functioning (Semple, Sullivan, Dunwoody, & Kernohan,
2004). For individuals who have received a diagnosis of HNCa, this gap may be particularly
expansive due to the profound biopsychosocial challenges they may experience related to
speech, swallowing, social interaction, pain, and depression. Consideration of the potential gap
between an individual’s current and ideal functional status may promote the notion that survival
alone is an insufficient indicator of the effectiveness of cancer treatment and, thus, shift the focus
of care to providing individuals with the maximum quality of life, in addition to providing
individuals with the maximum quantity of life (Semple et al., 2004).
Although it can be expected that one’s QoL is negatively influenced by HNCa, no simple
or linear relationship exists between the experience of the disease and dimensions of QoL
(Lawford & Eiser, 2001). Individuals’ capacity to rebound from their experience of surviving
HNCa and their appraisal of its overall impact, will idiosyncratically influence their perceived
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QoL (Lawford & Eiser, 2001). As such, substantial evidence exists to suggest that individuals
with similar cancer diagnoses and treatment statuses have divergent levels of perceived QoL
(Huber, Sillick, & Skarakis-Doyle, 2010). It is suggested that resilience may act as a central
factor to explain differing perceptions of QoL despite parallel circumstances (Tian & Hong,
2014). For instance, two individuals with comparable experiences of HNCa may vary
substantially in their perceived QoL as a function of the role played by resilience in their
subjective disablement experiences. In essence, resilience may substantially influence how one
fares following the completion of treatment for HNCa. Moreover, resilience may play a role in
buffering the influence of the adverse experience of HNCa and its treatment on survivors’ QoL.
The identification of resilience in individuals who have completed treatment for HNCa may
initiate acknowledgement of its value in acting as a potential protective process that may reduce
the impact of HNCa on one’s QoL and ultimately, bridge the gap between the kingdom of the
sick and the kingdom of the well.
In the sections to follow, a comprehensive introduction related to HNCa will be initially
presented. This will be followed by a presentation of the multifaceted concept of survivorship.
Introductory information pertaining to the constructs of resilience and QoL will subsequently be
provided. Finally, the statement of problem and rationale for the present study will be delineated.
Owing to the expansive array of challenges secondary to the experience of HNCa and its
treatment, the process through which HNCa survivors navigate the complex path back to
wellness is of particular interest. As such, the investigation of resilience in HNCa survivors may
elucidate its role in ameliorating the impact of HNCa and its treatment on survivors’ QoL.
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Head and Neck Cancer
HNCa is the sixth most common malignancy in the world, with approximately 650,000
new cases diagnosed annually (Howren, Christensen, Karnell, & Funk, 2012; Pai & Westra,
2009). HNCa refers to malignant tumours that originate from the epithelial lining of the
paranasal sinuses, nasal cavity, oral cavity, salivary glands, pharynx, and larynx (Howren et al.,
2012; Murphy, Ridner, Wells, & Dietrich, 2007). HNCa also includes tumours arising from the
craniofacial bones, soft tissues, skin, and neurovascular structures of the head and neck region
(Shah & Lydiatt, 1995; Pai & Westra, 2009). Malignancies found in the thyroid gland,
parathyroid gland, and the parapharyngeal space also fall under the extensive classification of
HNCa (Shah & Lydiatt, 1995). Head and neck cancers are predominantly squamous cell
carcinomas of the mucosal surfaces in the upper aerodigestive tract (Campisi & Giovannelli,
2009). Melanomas, sarcomas, lymphomas, and adenocarcinomas are other less common types of
head and neck tumours (Semple et al., 2004).
Staging of head and neck cancer. The American Joint Committee on Cancer TumourNode-Metastasis (TNM) staging system stipulates the staging criteria for HNCa (Vokes, 2012).
The TNM staging system categorizes malignancies based on their anatomic site and scope or
extent of disease (McQuade, Gunn, William, & Kies, 2016). For HNCa, the primary subsite of
the malignancy dictates the intricate parameters for both clinical and pathological staging of the
primary tumour (McQuade et al., 2016). The “T” classification describes the size of the primary
tumour. Vokes (2012) explained that “in general, primary tumours are classified as T1 to T3 by
increasing size, whereas T4 usually represents invasion of another structure such as bone, muscle,
or root of tongue” (Clinical Presentation and Differential Diagnosis, para. 7). The extent of
lymph node involvement is represented by the “N” classification. To categorize lymph node
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involvement, staging is based on the location of the involved lymph nodes (ipsilateral versus
contralateral to the primary tumour), as well as the size and number of nodes involved (Vokes,
2012). The degree of metastases, or spread of the cancer to other parts of the body, is described
by the “M” classification. For all HNCa sites, excluding the nasopharynx, the TNM staging
system has uniform criteria for making categorizations based on lymph node (N) involvement
and potential distant metastases (M) of the tumour (McQuade et al., 2016). Table 1 summarizes
common TNM staging for squamous cell carcinomas in the head and neck region, with the
exception of nasopharyngeal carcinomas.

Table 1
Common TNM Staging for Head and Neck Squamous Cell Carcinomas (Except Nasopharyngeal Carcinoma) *
Classification
Characteristic
T1
Tumour ≤ 2cm in greatest dimension
T2
Tumour > 2cm but < 4cm in greatest dimension
T3
Tumour > 4cm in greatest dimension
T4
Tumour invades adjacent structure
N0
N1
N2a
N2b
N2c
N3

No regional LNs
Single ipsilateral LN, ≤ 3cm
Single ipsilateral LN, > 3cm but < 6cm
Multiple ipsilateral LNs, none > 6cm
Bilateral or contralateral LN, none > 6cm
Any LN > 6cm

M0
M1

No distant metastasis
Distant metastasis

*LN = lymph node.
Note. From Correction, by S. Marur and A. A. Forastiere, 2008, Mayo Clinic Proceedings, 83(5), p. 604. Reprinted with permission.

Presentation of head and neck cancer. The presentation of HNCa varies according to
the stage and site of the primary tumour (Vokes, 2012). In general, early-stage head and neck
malignancies infrequently cause symptoms, but may manifest vague and minimal somatic
indications (Marur & Forastiere, 2008). Tumours that arise from the paranasal sinuses, nasal
cavity, and nasopharynx generally manifest in sinusitis (inflammation of a nasal sinus), nasal air
way obstruction, otitis media (inflammation of the middle ear), and epistaxis (bleeding from the
nose) (Marur & Forastiere, 2008; Vokes, 2012). Additionally, advanced nasopharyngeal
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carcinomas may also present with cranial nerve palsies (Marur & Forastiere, 2008). Painful
lesions and non-healing ulcers or sores are typical presentations of oral cavity malignancies
(Vokes, 2012). When tumours arise from structures that comprise the oropharynx, patients may
present with reduced mobility of the tongue, sore throat, dysphagia (impaired swallowing) or
odynophagia (painful swallowing), changes in voice, speech, and otalgia (ear ache) (Marur &
Forastiere, 2008; Vokes, 2012).
In later stages of cancers occurring in the hypopharynx, sore throat, hoarseness,
dysphagia, cervical adenopathy (enlargement of lymph nodes in the neck), and otalgia are
common symptoms (Marur & Forastiere, 2008; Vokes, 2012). Individuals with laryngeal cancer
may also present with hoarseness, however, the disease progression of cancers of the larynx may
vary with subsite (Marur & Forastiere, 2008; Vokes, 2012). For instance, glottic cancers (cancers
of the vocal folds) are often diagnosed early in the course of the disease and have higher success
rates of curative treatment (Marur & Forastiere, 2008). Conversely, supraglottic carcinomas
(lesions superior to the vocal folds) are typically diagnosed at later stages of the disease upon
discovery of a neck mass (Marur & Forastiere, 2008).
Etiology of head and neck cancer. The most common etiological factors of HNCa are
tobacco and alcohol (Marur & Forastiere, 2008). These substances contribute independently to
the development of HNCa, however, they are often used in combination and also act
synergistically to produce a multiplicative impact on carcinogenesis (Howren et al., 2012;
Muscat & Wynder, 1992; Rodriguez et al., 2003; Vokes, 2012; Wynder & Stellman, 1977). The
carcinogenic effect of tobacco is a result of the consumption of nicotine and polycyclic aromatic
hydrocarbons (Marur & Forastiere, 2008; Pai & Westra, 2009). Tobacco smoke effects the
tissues of the aerodigestive tract through the conversion of the carcinogenic compounds into
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reactive metabolites that interact with DNA through the action of oxidative enzymes (VargasFerreira et al., 2012). The genotoxic effect of the carcinogenic chemicals found in tobacco also
increases the risk of developing HNCa when individuals are subjected to passive smoking (Pai &
Westra, 2009).
Alcohol acts as a chemical solvent that heightens the risks associated with smoking by
“enhancing and prolonging mucosal exposure to the carcinogens present in tobacco smoke” (Pai
& Westra, 2009, p. 51). Extended exposure to the carcinogenic chemicals found in tobacco
enables the passage of the carcinogens into the cells of the mucous membrane of the upper
aerodigestive tract (Lee et al., 2007). The carcinogenic influence of alcohol and tobacco
consumption can be observed at the level of the squamous cells that line the mucous membranes
in the form of substantial damage to the DNA contained in these cells (Scully, Field, & Tanzawa,
2000). For instance, squamous cell carcinoma in the head and neck region commonly occurs as a
result of extensive molecular damage to the DNA and consequent cell dysregulation that occurs
secondary to “disruption of cell signaling, the cell growth cycle, or mechanisms to repair cell
damage or eliminate dysfunctional cells” (Scully et al., 2000). The progressive assemblage of
DNA damage ultimately leads to autonomous division of the squamous cells that eventually
results in carcinoma (Scully et al., 2000). The process of alcohol-related carcinogenesis in the
head and neck region is also attributable to the metabolism of ethanol into the metabolite
acetaldehyde (Seitz & Stickel, 2007). Acetaldehyde binds to segments of DNA to form DNA
adducts that hinder DNA synthesis and repair and are commonly the beginning of carcinogenesis
(Pai & Westra, 2009; Seitz & Stickel, 2007).
Traditionally, smoking trends have mirrored the rate of oropharyngeal cancer (Pai &
Westra, 2009). However, over the span of the last 20 years the incidence of oropharyngeal cancer
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has increased substantially without any corresponding increase in smoking trends (Pai & Westra,
2009; Walden & Aygun, 2013). Subtypes of the Human Papilloma Virus (HPV) are now
recognized as being the reason for the divergence between oropharyngeal cancer trends and
smoking trends. HPV is also responsible for shifting the demographics of oropharyngeal
carcinomas towards younger non-smoking individuals (Marur & Forastiere, 2008; Pai & Westra,
2009). Fortunately, HPV positive oropharyngeal malignancies have a more favourable prognosis
and are associated with increased survival since HPV positive tumours have heightened
sensitivity and responsivity to radiation and chemotherapy (Howren et al., 2012; Marur,
D’Souza, Westra, & Forastiere, 2010; Vokes, 2012).
The Epstein-Barr virus is another common viral etiological factor of HNCa (Howren et
al., 2012; Marur & Forastiere, 2008). While HPV is commonly linked to oropharyngeal cancers,
the Epstein-Barr virus is recognized as being a causative factor in the development of
nasopharyngeal carcinomas (Howren et al., 2012; Vokes, 2012). It is also worth noting that other
etiological factors of HNCa include diet; oral hygiene; carcinogen exposure to nickel, chromium,
radium, mustard gas, and asbestos; infectious agents; marijuana use; family history and preexisting health conditions (Marur & Forastiere, 2008; Pai & Westra, 2009). Regardless of
etiology, the treatment modality acts as an additional factor that further effects an individual’s
experience with HNCa.
Treatment of Head and Neck Cancer
The treatment for HNCa and the associated treatment morbidities that may affect
physical, psychological, and social functioning have the potential to substantially influence an
individual’s journey through HNCa and intensify the experience of living with a life-threatening
disease (Johansson, Ryden, & Finizia, 2008). Treatment for the management of HNCa
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commonly includes surgery, radiation therapy, chemotherapy, or multimodal approaches (Marur
& Forastiere, 2016). Surgery alone may be sufficient to remove an early-stage tumour, however,
more aggressive surgical procedures may be utilized when organ-preserving therapies that seek
to retain anatomic structure of the affected site, are deemed insufficient as the sole treatment
modality (Marur & Forastiere, 2016). Additionally, salvage surgery may be done when radiation
or chemotherapy fail (Argiris, Karamouzis, Raben, & Ferris, 2008). Radiation therapy may be
used in isolation, adjunctively with surgery, or concurrently with chemotherapy (Marur &
Forastiere, 2016). Chemotherapy is commonly used as part of initial multimodal treatment of
HNCa, but generally only as adjuvant treatment (Marur & Forastiere, 2016).
Complete tumour eradication is the primary goal of treatment, however, the preservation
of structure and function, minimization of treatment sequelae, and maximization of QoL should
also be central to treatment choice (Shah & Lydiatt, 1995). Nonetheless, the TNM staging of the
tumour provides foundational information that guides the treatment decision process. For
instance, surgery or radiation are generally deemed to be the optimal singular treatment modality
for early-stage tumours staged as T1 or T2 that do not involve nearby lymph nodes or distant
metastases (Marur & Forastiere, 2008; McQuade et al., 2016; Vokes, 2012). A multimodal
treatment approach that includes concomitant chemoradiation therapy (CRT) is standard for
intermediate tumours staged as T2 or T3 with N0 to N1 lymph node involvement that are either
unresectable or resectable, but require further treatment postoperatively (Marur & Forastiere,
2008; McQuade et al., 2016; Vokes, 2012). Optimal treatment plans for advanced HNCa, staged
as T3 or T4, with lymph node involvement characterized as N2 or N3, generally consist of one of
the following three multimodal treatment strategies:
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(1) induction, also known as neoadjuvant therapy, with chemotherapy given before
surgery or radiation; (2) concomitant chemoradiation, with chemotherapy given
simultaneously with radiation to enhance its effect; [or] (3) adjuvant therapy, where
chemotherapy is given after surgery or radiation in an effort to decrease microscopic
metastatic disease burden. (McQuade et al., 2016, Combined-Modality Therapy section,
para. 1)
Consideration of the TNM staging must also be balanced with consideration of the
anatomical location of the tumour and associated risk of lymphatic system involvement in order
to determine the optimal treatment modality (Shah & Lydiatt, 1995; Walden & Aygun, 2013).
For instance, when the primary tumour occurs in the larynx, radiation therapy is often the
selected treatment method so that the structure of the larynx remains intact and voice and
swallowing functions can be preserved (Walden & Aygun, 2013; Vokes, 2012; Shah & Lydiatt,
1995). Conversely, surgery is often deemed the optimal treatment modality when the primary
tumour arises out of the oral cavity so that long-term side effects of radiation including xerstomia
(sensation of dry mouth) and dental decay are prevented (Vokes, 2012). Depending on the
amount of involvement of the base of tongue, constrictor muscles, and epiglottis, prevention of
aspiration and conservation of the swallowing function and speech are central considerations in
treatment decisions for tumours that occur in the oropharynx or hypopharynx (Walden & Aygun,
2013). Accordingly, in an attempt to preserve the structure of the pharynx, radiation is often the
preferred treatment for nasopharyngeal and oropharyngeal tumours (Shah & Lydiatt, 1995).
Since nasal cavity or paranasal sinus carcinomas rarely present at an early stage, surgery is
generally the definitive treatment option for such tumours (Shah & Lydiatt, 1995).
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Regardless of the treatment modality selected, the management of HNCa carries a
significant risk to individuals’ functioning in the pursuit of achieving a biological cure
(McQuade et al., 2016). Therefore, the grueling effects of the treatment associated with HNCa
often add substantial burden to an individual’s experience with cancer (Pauloski, 2008) and
subjects the individual to profound disablement. Disablement can be conceptualized as the
influence of chronic and acute health conditions on an individual’s functioning at intrapersonal,
interpersonal and environmental levels (Jette, 2006). From a biopsychosocial perspective, an
individual’s experience of disablement can be considered to be an outcome of the dynamic
interaction of biological, personal, and social forces (Jette, 2006). As such, not only does HNCa
cause substantial disablement, but surgery, radiation therapy, and chemotherapy commonly have
a significant influence on HNCa survivors’ process of recovery owing to the consequential
decrements to multiple domains of functioning (DeBoer, McCormick, Pruyn, Ryckman, & Van
Den Borne, 1999).
Even after treatment for HNCa has concluded, the effects of treatment continue to impact
the individual in domains of physical, psychological, and social functioning. Owing to the
complexity of the anatomical location and necessity of the pathological function of the region
affected by HNCa, surgery, radiation therapy, and chemotherapy have the potential to result in
substantial physical, psychological, and social treatment sequelae that are highly interrelated
(Newell, Sanson-Fisher, Girgis, & Ackland, 1999).
Treatment sequelae: Physical domain of functioning. Significant treatment sequelae
may occur secondary to surgery, radiation therapy, and/or chemotherapy that impair an
individual’s functioning in the physical domain. Radical surgery for HNCa often significantly
modifies the structure and function of organs which may lead to disfigurement or loss of speech
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and swallowing function (McQuade et al., 2016). Although uncommon, postoperative
complications associated with surgery for HNCa may include infection, fistula (an atypical
fusion between tubal organs, such as those in the head and neck region), wound dehiscence (the
rupture of a surgical wound along the sutures), haematoma (a pooling of blood outside the blood
vessels), seroma (a collection of fluid in a tissue or an organ), and flap necrosis (death of tissue
that has been relocated from one location of the body to another) (Derks, De Leeuw, Hordijk, &
Winnubst, 2003).
Nevertheless, nonsurgical treatment modalities also have the potential to cause harm to a
patient’s physical functional status (McQuade et al., 2016). Although radiation therapy is
primarily prescribed for curative purposes, this modality has the perceived benefit of preserving
structures of the head and neck (Pauloski, 2008). It could be assumed that if macroscopic
structure is preserved, the function of the exposed anatomical region will also be maintained. In
actuality, radiation therapy for HNCa is prescribed for tumour eradication, however, radiation
therapy commonly results in substantial negative consequences in relation to physical
functioning that may nullify the benefits of organ preservation accomplished (Adelstein et al.,
2000). The disabling side effects of radiation therapy are a result of damage to soft tissue
structures that are within the radiation treatment volume, including tendons, ligaments, fascia,
muscles, and fibrous and connective tissues (Murphy & Gilbert, 2009). In response to the
inflicted damage, an inflammatory reaction in this anatomical region is triggered, which in turn
causes radiation-induced fibrosis (Murphy & Gilbert, 2009). Fibrosis in the irradiated tissues is
demarcated by a diffuse scarring process that ultimately causes the tissue to become less elastic
(Pauloski, 2008). Additionally, because radiotherapy uses reactive oxygen species to destroy
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cancerous cells, chronic oxidative stress causes the perpetuation of tissue damage that results in
ongoing side-effects long after the completion of the radiotherapy (Murphy & Gilbert, 2009).
Howren et al. (2012) explained that during the course of radiotherapy, “the importance of
pain as a patient-reported outcome cannot be overstated as at least half of [HNCa] patients will
experience some degree of pain” (p. 15). Pain is a very common and significant side-effect
associated with radiotherapy for the treatment of HNCa due to the structural damage to the oral
mucosa that results in mucositis (Pauloski, 2008). Mucositis is characterized by ulceration of the
mucous membranes that line the tissues in the field of radiation and is caused by the
consequential increase in levels of reactive oxygen species utilized by the radiotherapy to destroy
the cancerous cells (Pauloski, 2008). Functionally, the pain and ulceration of mucositis impairs
chewing, swallowing, and manipulation of food in the mouth and may lead to dehydration,
malnutrition, and weight loss (Vokes, 2012). As a result of radiation therapy, severe ulceration
associated with mucositis, in conjunction with an immobile larynx as a result of the radiationinduced fibrosis, may lead to the narrowing or complete closure of the pharynx or esophagus,
referred to as stricture (Pauloski, 2008). Stricture results when the anterior and posterior mucosal
surfaces heal together which causes adhesion and the ultimate closure of the pharynx or
esophagus (Pauloski, 2008). Stricture limits the passage of liquid and food which has a
significant impact on swallowing function and the risk of malnutrition and weight loss (Pauloski,
2008).
Dysphagia refers to the disruption of the swallowing function that causes difficulty with
the transport of solids or liquids from the mouth to the stomach and may be the result of fibrosis
and stricture caused by radiation for HNCa (Gaziano, 2002). Coincidentally, damage to the
salivary glands caused by radiotherapy causes a substantial decrease in salivary flow, referred to

14

as hypofunction of the salivary glands (Pauloski, 2008). Thus, an individual’s experience with
dysphagia is commonly augmented by the perception of dryness in the oral cavity, referred to as
xerostomia, which is commonly associated with salivary gland hypofunction (Pauloski, 2008).
Chemotherapy is also associated with a host of disabling side-effects. A common
treatment sequela of chemotherapy is myelosuppression, which refers to a decrease in bone
marrow activity that causes a decline in red blood cells, white blood cells, and/or platelets,
(Vokes, 2012). Myelosuppression can result in fatigue, dizziness, and the body’s diminished
ability to fight infection and disease (Zangemeister-Wittke & Simon, 2012). Kidney damage
(nephrotoxicity) may be a further complication of chemotherapy (Vokes, 2012). Individuals may
also experience nausea, vomiting, mucositis, and dysgeusia (alteration of the perception of taste),
all of which make maintaining adequate nutrition a difficult task (Vokes, 2012). To further
complicate matters of nutrition, chemotherapy may also result in dysphagia, xerostomia, fibrosis,
and pharyngeal scarring that may lead to feeding-tube dependence (Marur et al., 2010).
Treatment sequelae: Psychological domain of functioning. The extensive array of
physical sequelae of HNCa treatment is paralleled by substantial distress characterized by
marked psychological dysfunction (Bornbaum, Doyle, Skarakis-Doyle, & Theurer, 2013;
Bornbaum et al., 2012; Semple et al., 2004). The National Comprehensive Cancer Network
Distress Management Panel defines distress in the context of an individual’s experience with
cancer as:
a multi-determined unpleasant emotional experience of a psychological (cognitive,
behavioural, emotional), social, and/or spiritual nature that may interfere with the ability
to cope effectively with cancer, its physical symptoms, and its treatment. Distress extends
along a continuum, ranging from common normal feelings of vulnerability, sadness, and
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fears to problems that can become disabling, such as depression, anxiety, panic, social
isolation, and spiritual crisis. (as cited in Carlson & Bultz, 2004, p. 838)
HNCa patients’ experience of distress, specifically depression, either as clinical depressive
disorder or subclinical symptomology, is notable since the prevalence of depression is higher in
individuals with HNCa than in individuals with other cancer diagnoses (Howren et al., 2012).
This is understandable since the experience of distress is associated with the physical and social
sequelae of treatment that are particularly grueling for individuals with HNCa. For instance, a
positive correlation exists between high levels of distress and intense experiences of physical
sequelae, such as pain, fatigue, and nausea, and social sequelae, such as social isolation and
relationship disruption (Aaronson, 1991; Bjordal & Kaasa, 1995; Kugaya et al., 2000; Newell et
al., 1999).
It is worth noting that transient negative emotions are a natural and common response to
an adverse life event such as the experience of HNCa and its treatment (McDonough, Boyd,
Varvares, & Maves, 1996). In other words, depressive feelings are a normal and foreseeable
element of the HNCa experience. However, in a select group of individuals with HNCa, the
depressive feelings may persist to a degree that substantially inhibits coping for a period of time
that is considered extensive enough to determine that the expected negative feelings have
transitioned to dysfunctional depressive symptoms (Haman, 2008; McDonough et al., 1996).
When normal negative feelings become dysfunctional, the underlying cause of the depression
must be determined and addressed in order to avoid serious potential implications of the
experience of depression (McDonough et al., 1996).
One potential implication is that the experience of depression secondary to HNCa and its
treatment substantially impairs an individual’s ability to return to pre-diagnosis functioning in
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domains of speech, eating, and social interactions (Howren et al., 2012). Depression may also
impact a HNCa patient’s immune response, habits of self-care, treatment compliance, and risk of
malnutrition (Howren et al., 2012). Furthermore, it is suggested that depression and
psychological dysfunction that result from the disabling physical and social side-effects of HNCa
and its treatment are probable contributing factors for the majority of suicides in those with
HNCa (Kendal, 2007). Concerningly, the incidence of suicide is highest in individuals who have
received a diagnosis of HNCa compared to individuals who have received other cancer
diagnoses (Bjordal & Kaasa, 1995; Kendal, 2007; Misono, Weiss, Fann, Redman, & Yueh,
2008). This high suicide rate is telling of the significant burden of HNCa and its treatment.
Due to the anatomical location of the structures impacted by HNCa and its treatment,
visible disfigurement is another common treatment outcome that has the potential to contribute
to psychological dysfunction. It is almost impossible for many individuals who have received
treatment for HNCa to conceal the signs of the disease and its treatment (Howren et al., 2012;
Nash, 2014; Semple et al., 2004). The unconcealable signs of HNCa treatments often cause
individuals to experience challenges related to intimacy, making friends, and acquiring jobs
(Howren et al., 2012; Semple et al., 2004). Visible disfigurement may also augment distress,
depression, and social anxiety and isolation (Howren et al., 2012; Semple et al., 2004).
Additionally, permanent disfigurement often has noteworthy implications for the individual’s
body-image, self-esteem, and self-concept (Cohen et al., 2015; Gritz et al., 1999; Murphy et al.,
2007; Nash, 2014).
The physical treatment sequelae of HNCa that influence an individual’s psychological
functioning are not only visually apparent, but also auditorily apparent (Doyle, 2005). HNCa is
unique in that it is the only form of cancer that alters the “structural integrity to effectively
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communicate, or in some instances render the individual unable to verbally communicate at all”
(Doyle, 2005, p. 11). As a result of the extreme visibility of HNCa and its treatment, those with
HNCa may be exposed to unsolicited and untoward staring and comments (Semple et al., 2004).
Correspondingly, individuals with HNCa are at a heightened risk of feeling stigmatized in
society (Howren et al., 2012; Semple et al., 2004). Goffman explained that “stigmatizing
conditions, whether real or perceived, cannot be overlooked because they threaten the
individual’s judgment of self, which might then pose a risk to relationships within the
individual’s own social milieu” (as cited in Doyle, 2005, p. 11).
Treatment sequelae: Social domain of functioning. The functional impairment
associated with HNCa and its treatment also exerts a wide-ranging influence on the individual’s
social functioning. Several of the physical treatment sequelae of HNCa treatments, including
dysphagia, xerostomia, dysgeusia, and mucositis, can impair individuals’ ability to engage in
shared meal times in social settings which can lead to social isolation (Pateman, Ford, Batsone,
& Farah, 2015; Threats, 2007). The consequential restricted social involvement may be an
outcome of the perceived indignity of the restricted food choices necessitated by swallowing and
chewing dysfunction that result from the aforementioned physical sequelae of HNCa treatment
(Patterson, McColl, Wilson, Carding & Rapley, 2015). Individuals may be influenced to select
social engagements carefully to avoid the added burden of social tension or pressure that could
result from a clash between the challenges of dysphagia and socially constructed norms, which
can lead to further social isolation (Nund et al., 2014).
Furthermore, socially constructed eating and drinking customs are associated with
significant symbolic value (DeRenzo, 1997). The social customs surrounding eating and drinking
influence food choices, acceptable methods of consumption and the accepted timing of meals
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(DeRenzo, 1997). Unfortunately, individuals who have undergone treatment for HNCa may no
longer be able to conform to these social customs of eating. The added perception of not
conforming to social norms can augment the burden of the physical HNCa treatment sequelae
and concomitant social isolation. An individual’s experience with dysphagia, xerostomia,
dysgeusia, and mucositis can promote the attribution of a strictly nutritional and survival based
meaning to food that may clash with social customs of food that have minimal connection to
nutritional factors but are instead in place to define and solidify social relations (DeRenzo,
1997).
Poor speech intelligibility may be an additional result of HNCa treatment, which may
further complicate and inhibit an individual’s desire or capacity to engage socially (Semple et al.,
2004). Not only does an individiual’s inhibited ability to communicate with others augment
issues of social isolation, it may also lead to feelings of embarrassment, lowered self-esteem, and
depression which in turn, may impede adherence to rehabilitation or self-care regimens, as well
as tobacco and alcohol cessation programs that are crucial for HNCa survivors (Blood, Luther, &
Stemple, 1992; Blood et al., 1994; Howren et al., 2012). The extensive range of social challenges
faced by individuals who have undergone treatment for HNCa is particularly concerning since it
is well documented that social support is correlated with positive adjustment to the experience of
disease (McDonough et al., 1996). In essence, is it concerning that the population of HNCa
survivors faces a profoundly disabling disease, while also being at an elevated risk for significant
social isolation.
The range of deficits experienced by individuals who have received a diagnosis of HNCa
are multidimensional and highly interdependent. Accordingly, HNCa is commonly considered to
be the most emotionally traumatic cancer diagnosis as a result of the extensive concomitant
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biopsychosocial sequelae (Bornbaum et al., 2012). Thus, despite over 4,300 new diagnoses in
Canada each year, the impact of HNCa on those who receive this diagnosis far exceeds the
incidence of the disease (Canadian Society of Otolaryngology – Head & Neck Surgery, 2013;
Giuliani et al., 2016).
Since the beginning of the twenty-first century, substantial medical advances have been
made that have improved the efficacy of HNCa treatments (Giuliani et al., 2016; Stanton,
Rowland, & Ganz, 2015; Wells, Semple, & Lane, 2015). The advanced techniques for
eliminating the disease may yield a more probable medical cure, however, newly cured
individuals may be bestowed with residual trauma that leaves them far from healed. The
extensive array of the biopsychosocial treatment sequelae of the advanced treatment modalities
illustrates that achieving curative intent is often at the expense of the individual’s QoL. In
essence, the increasing quantity of life provided by the treatment advancements does not
necessarily equate to increasing quality of life. Furthermore, increased quantity of life does not
mean that an individual’s struggle to cope with and adapt to the disablement experience of HNCa
will cease when the transition is made from cancer patient to cancer survivor. In actuality, a new
assortment of challenges arises following the completion of curative treatment for HNCa as
“survivors experience changes in the frequency of contact with their healthcare team, manage the
lingering side effects of treatment, and resume important social roles and activities—all of which
can precipitate feelings of distress” (de Moor et al., 2013, p. 562). The collective multifaceted
experience of the cancer survivor that is associated with these new challenges is commonly
referred to as survivorship (Miller & Shuman, 2016).
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Survivorship
It is estimated that approximately two-thirds of individuals diagnosed with HNCa will
survive the disease; a figure that is expected to rise with continued advancements in detection
and treatment of HNCa (Giuliani et al., 2016; Semple et al., 2004; Stanton et al., 2015). Hassey
Dow (2003) explained that the rising number of cancer survivors is also attributable to “changes
in the fundamental understanding of genetics, rapid translation of basic science to practice,
modification of dose-limiting toxicities, an increase in screening and early detection activities,
enhanced rehabilitation and support interventions, and changes in sociocultural factors” (p. 455).
Additionally, due to the more favourable prognosis of human papillomavirus-positive oral and
oropharyngeal cancers, a projected 90% of HNCa survivors will experience long-term (e.g., > 5
years) survival (LaMonte, 2016; Marur et al., 2010; Vokes, 2012). As a result, there has been a
substantial increase in the number of individuals who are surviving HNCa and living longer after
diagnosis and treatment of the disease (Giuliani et al., 2016).
From a biomedical perspective, the notion of survival may be understood as a static state
of being cancer free, however, survivorship cannot be reduced to a categorical measure of the
efficacy of cancer treatment (Miller & Shuman, 2016). If survivorship is considered through a
biopsychosocial lens, it becomes apparent that for individuals who have survived HNCa,
survivorship is a more complex notion that encompasses the act and process of living through
and beyond the diagnosis and treatment (Brearley et al., 2011; Feuerstein, 2007a; Miller &
Shuman, 2016; Mullan, 1985). Accordingly, widely accepted conceptualizations of survivorship
posit that an individual is considered a survivor, and, thus, enters the survivorship phase of the
cancer continuum at the time of initial diagnosis (Giuliani et al., 2016; Miller & Shuman, 2016).
It is suggested that “survival begins at the time of diagnosis since that is the point at which
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[individuals] must confront their own mortality and the inevitable change in the course of their
life moving forward” (Miller & Shuman, 2016, p. 1).
Beginning at the time of diagnosis and continuing until the end of life, survivorship can
be conceptualized as a continuous and fluid state (Brearley et al., 2011; Miller & Shuman, 2016).
Miller and Shuman (2016) posited that “survival does not occur in a vacuum,” (p. 1) as
evidenced by the “medical, psychosocial, interpersonal, financial, and functional consequences
of disease and its therapies [that] all contribute to [the] experience of the cancer survivor” (Miller
& Shuman, 2016, p. 1). As such, the notion of survivorship encompasses the dynamic process of
navigating the challenges that are associated with individuals’ adjustment and adaptation to the
altered life course that evolves from their experience with HNCa. It is worth noting in light of the
variety of survivorship definitions that exist, that this conceptualization of survivorship has been
employed for the context of this study in order to portray a holistic representation of individuals’
experience with HNCa. Furthermore, this definition of survivorship has been selected to
highlight the range of biopsychosocial challenges associated with an individual’s experience
with HNCa that begin at the time of diagnosis and persist for years after the individual has
completed treatment.
An increased risk of compromised physical and psychosocial outcomes commonly
accompanies the challenges of adjusting to life after cancer (Molina et al., 2012). Evidence
suggests that individuals who have received a diagnosis of cancer have the potential to exhibit
positive psychosocial adjustment over time; however, a subset of survivors becomes susceptible
to diminished psychosocial and physical health, that may arise from the persistent effects of
HNCa and its treatment (Stanton et al., 2015). Residual effects of the diagnosis and treatment of
cancer can be categorized into long-term and late effects (Cohen et al., 2015). Long-term effects

22

are demarcated as medical complications acquired during active treatment that continue after
treatment completion (Cohen et al., 2015). Medical problems that arise months or years after
treatment completion are categorized as late effects (Cohen et al., 2015). Wolff (2007) explained
that while the conceptualization of survivorship has “shifted from a narrow focus on the direct
effects of anti-cancer therapy” (p. 7), it is still important for the notion of survivorship to
encompasses traditional outcomes of cancer and its treatment such as long-term and late effects.
Due to the functional significance of the anatomical region affected by HNCa and its
treatment, individuals who have received treatment face an overwhelming collection of longterm and late effects (Cohen et al., 2015; Murphy et al., 2007; Hutton & Williams, 2001). The
development of physical long-term and late effects may be influenced by several variables,
including type, duration and dose of treatment, location of primary tumour, the presence of
regional or distant disease, and patient demographic factors (Cohen et al., 2015). Common
physical long-term and late effects of HNCa and its treatment are presented in Table 2. In
addition to myriad physical long-term and late effects, a multitude of psychosocial sequelae have
also been reported to affect HNCa survivors (Molina et al., 2012; Coughlin, 2008; Stanton et al.,
2015). General psychosocial long-term and late effects are summarized in Table 3. It is worth
noting that in many cases, these psychosocial effects of survivorship “are more challenging than
the defined course of direct anti-cancer therapy” (Wolff, 2007). Moreover, since the
psychosocial aspects of the disease are commonly more arduous to contend with than the
physical aspects, unresolved suffering in the psychosocial domain of disablement often results in
diminished coping and adjustment (McDonough et al., 1996). Concurrent consideration of the
physical and psychosocial domains of disablement is advantageous because it allows healthcare
providers to observe the influence of each domain on the individual’s attitude, behaviour, and
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well-being, as well as their compliance and use of healthcare resources (McDonough et al.,
1996).
Furthermore, the physical and psychosocial long-term and late effects faced by posttreatment HNCa survivors have a profound effect on their functioning and perceived QoL
(Murphy et al., 2007; Bjordal & Kaasa, 1995). As such, the awareness and management of the
multitude of treatment sequelae must continue even after the completion of treatment, thereby
indicating that active holistic care must also encompass the survivorship phase of the cancer
continuum (Miller & Shuman, 2016; Stanton et al., 2015). In essence, owing to the long-term
and late effects of HNCa, there is a substantial need to provide survivors with support and
assistance through their process of adjusting to the disabling physical and psychosocial
treatment-related challenges associated with survivorship (Bornbaum, 2013).
Unfortunately, due to the physical focus of oncological care provision, patients may be
hesitant to disclose psychosocial concerns, contributing to common psychosocial challenges
“remaining undisclosed and only becoming apparent when [associated] symptoms [of
psychosocial morbidity] are overt and individuals are no longer able to cope” (Bornbaum et al.,
2012, p. 2163). However, attending to the psychosocial dimension of an individual’s experience
with HNCa may serve to decrease the extreme strain placed on the healthcare system by the
high-utilizers of care who are predominantly those who are experiencing substantial
psychosocial morbidity, such as anxiety, depression, and mood disturbances (Carlson & Bultz,
2004). Moreover, if the psychosocial aspects of disablement are highlighted so that health care
providers are tuned in to the psychosocial struggles of individuals with HNCa, those who are
struggling to cope, and often represent the highest utilizers of care, may be identified and
supported proactively before psychosocial morbidity can firmly manifest. This would ultimately
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maximize benefits and savings to the healthcare system (Carlson & Bultz, 2004). For instance,
increased attention to individuals’ psychosocial disablement experience with HNCa has been
linked to improved medical outcomes and increased patient satisfaction in addition to decreased
health care costs (Bornbaum et al., 2012).
Despite delivering a medical cure, therapeutic endeavors that neglect individuals’
subjective experience of disablement can threaten their ability to be resilient in psychological
and social domains of well-being (Frank, 1995). In essence, when subjective domains of
disablement are ignored, individuals who have completed treatment often reach the end of the
clinical pathway before their psychosocial functioning has returned to a homeostatic level. In
other words, the clinical pathway rectified the abnormal cell growth that was the cause of the
individual’s disablement experience with HNCa but has done nothing to encourage or support a
resilient response in the survivor. Based on the above considerations, there is a need to
investigate the potential for resilience to ameliorate the impact of the biopsychosocial
consequences of HNCa and its treatment, not only in hopes of maximizing survivors’ QoL, but
also to minimize the strain on the healthcare system.
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Table 2
Summary of Potential Long-Term and Late Effects of Head and Neck Cancer and its Treatment by Treatment Type
Treatment Type
Long-Term Effects
Late Effects
Surgery
Shoulder function
•
Spinal nerve abnormalities
(neck dissection,
•
Shoulder mobility, pain
•
Lymphedema
laryngectomy)
•
Neuropathy
Oral health complications
•
Cervical radiculopathy
•
Xerostomia
•
Dysphagia
•
Oral infections
Musculoskeletal effects
•
Trismus
•
Impaired neck motion, pain
•
Stricture
Radiation
(IMRT, mediastinal RT)

Oropharyngeal
•
Xerostomia
•
Dysphagia
Neuromuscular
•
Cervical dystonia
•
Trismus
Musculoskeletal
•
Shoulder dysfunction
Integumentary
•
Radiation dermatitis
Lymphovascular
•
Lymphedema
Oral health complications
•
Xerostomia
•
Oral infections

Vision
•

Premature cataracts

Cardiovascular
•
Carotid obstruction
•
Baroreceptor failure
Oropharyngeal
•
Xerostomia
•
Dysphagia
•
Dysarthria
Pulmonary
•
Pulmonary fibrosis
Neuromuscular
•
Cervical dystonia
•
Trismus
•
Brachial plexopathy
•
Cervical radiculopathy
Musculoskeletal
•
Osteonecrosis
Lymphovascular
•
Lymphedema
•
Carotid stenosis
Sensory complications
•
Hearing loss
•
Ocular issues
•
Dysgeusia or loss of taste

Chemotherapy

Neuromuscular
•
Sensory/motor neuropathy
•
Sensory ataxia
•
Gait dysfunction
•
Vertigo

Neuromuscular
•
Cardiac abnormality, cardiomyopathy
Other
•
•
•

Osteoporosis, fractures
Metabolic syndrome
Other effects
Cardiovascular disease – possible increased risk
of myocardial infarction
•
Hot flushes/sweats
•
Diabetes; decreased sensitivity to insulin and
•
Weight gain, abdominal obesity
oral glycemic agents
•
Fatigue/decrease activity
•
Increased cholesterol
•
Anemia
•
Increased fat mass and decreased lean muscle
•
Body hair loss
mass/muscle wasting
•
Dry eyes
•
Venous thromboembolism
•
Vertigo
•
Cognitive dysfunction
Note. From American Cancer Society Head and Neck Cancer Survivorship Care Guidelines, by E. E. W. Cohen et al., 2015, A Cancer Journal for Clinicians,
66(3), p. 213. Reprinted with permission.
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Table 3
General Psychosocial Long-Term and Late Effects
•
Depression, depressive symptoms
•
Distress – multifactorial unpleasant experience of psychological, social, and/or spiritual nature
•
Worry, anxiety
•
Fear of recurrence
•
Pain-related concerns
•
Changes in sexual function and/or desire
•
Challenges with body image (secondary to surgery, laryngectomy, radiation)
•
Challenges with self-image
•
Relationship and other social role difficulties
•
Return to work concerns and financial challenges
Note. From American Cancer Society Head and Neck Cancer Survivorship Care Guidelines, by E. E. W. Cohen et al., 2015, A Cancer Journal for Clinicians,
66(3), p. 214. Reprinted with permission.

To reflect the myriad short and long-term challenges concomitant with survivorship,
three phases have been suggested to demarcate typical groupings of potential long-term and late
effects. The three phases of survivorship were proposed by Mullan and include “‘acute survival,’
the phase that includes diagnosis and treatment; ‘extended survival,’ the phase that begins at the
completion of intensive therapy and includes surveillance; and ‘permanent survival,’ a phase
vaguely defined as the period of cure” (as cited in Miller & Shuman, 2016, p. 1). Although
specific challenges and experiences may be representative of a certain survivorship phase, the
heterogeneity of survivors renders the three phases fluid and dynamic (Feuerstein, 2007a;
Stanton et al., 2015). At the outset of their experience with HNCa, individuals encounter a
unique subset of challenges related to the diagnosis and treatment that are reflected in the acute
phase of survivorship.
Acute phase of survivorship. At the time of diagnosis and commencement of the acute
survival phase, the “emotional stress of simply being characterized as a ‘patient with cancer’
coupled with the realization that [the individual] may bear substantial functional impairment can
be significant – even in the event of cure” (Miller & Shuman, 2016, p. 2). This psychosocial
disruption elicited by the diagnosis of cancer is evidenced by a higher representation of
symptoms of depression and anxiety in survivorship populations (Cohen et al., 2015; Stanton et
al., 2015). Mullan (1985) posited that anxiety secondary to the diagnosis of cancer instigates a
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“state of mental ill-being that is sometimes more punishing than the biologic presence of the
disease” (p. 271). Nonetheless, the “biologic” and physical symptoms of the head and neck
malignancies may be already weighing heavily on the individual at the time of initial diagnosis
(Miller & Shuman, 2016). For instance, newly diagnosed individuals may already be suffering
from speech deficits, dysphagia, fatigue, and pain (Brearley et al., 2011; Cohen et al., 2015; Gritz
et al., 1999).
When individuals receive a diagnosis of HNCa they embark on a journey that often
creates chaos in all aspects of their daily functioning (Semple et al., 2004). While the duration of
the acute survival phase is generally only a few weeks, the time following the initial diagnosis of
HNCa is characterized by an inundation of unfamiliar and potentially frightening encounters
concomitant with the diagnosis (Miller & Shuman, 2016). At the time of diagnosis, the
individual is forced to quickly assimilate a large amount of information about their disease and
the corresponding treatment options (Semple et al., 2004). Individuals in the acute phase:
confront in rapid succession a number of … issues: treatment options; the immediate
interpersonal and financial consequences of therapy, including time away from work and
income and myriad others; treatment-associated pain and morbidity; the risks inherent to
head and neck surgery, radiotherapy, and/or chemotherapy; acquiring new skills, such as
tracheostomy, gastrostomy, and wound care; and potentially even anger or guilt over the
factors contributing to their development of the disease. (Miller & Shuman, 2016, p. 2)
When individuals encounter the treatment related challenges of the acute survivorship
phase, the aforementioned challenges associated with the diagnosis are compounded by disabling
symptoms that are a direct effect not of the cancer, but of the treatment itself. Unfortunately, the
completion of treatment does not equate to the completion of challenges faced by HNCa
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survivors. When individuals enter the extended phase of survivorship they are confronted with a
new subset of challenges.
Extended phase of survivorship. Tasks of reassimilation and reentry characterize the
extended survival phase that commences following treatment completion (Miller & Shuman,
2016). An individual who has survived a cancer diagnosis and treatment, may be poorly prepared
for the reentry period that categorizes the transition from active cancer patient to cancer survivor
(Stanton et al., 2015; Mullan, 1985). Consequently, individuals who have survived HNCa, as
well as their significant others and caregivers, may hold “unrealistically lofty expectations for
rapid recovery … and [may be] surprised by their feelings as treatment ends” (Stanton et al.,
2015, p. 161). Individuals may expect that both their health and daily routines will begin to
stabilize now that the rigmarole of active treatment has ended (Brearley et al. 2011). However,
this expectation may not be entirely realistic and individuals may now face the challenge of
readjusting to a new normal. There exists a somewhat myopically comforting linearity of the
events associated with the active treatment of HNCa that is discontinued subsequent to treatment
completion. Stanton et al. (2015) explained that:
the months after treatment typically involve loss of the safety net of active treatment and
the accompanying supportive milieu offered by frequent visits to health care providers,
resumption or alteration of former roles within and outside the home, a decline in social
support, and experience of lingering or emerging physical and psychological effects of
diagnosis and treatment. (p. 162)
Following recovery from HNCa and its treatment, continued cancer surveillance,
innocuous symptoms that may mimic cancer, or the cancer related illness or death of a public
figure or family member, can trigger anxiety and distress surrounding fear of recurrence
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(Coughlin, 2008; Rolland, 2005; Stanton et al., 2015). Fear of cancer recurrence has a significant
impact on individuals who are in the extended phase of survivorship and, thus, should not be
minimized (Doyle, 1994). Fear of cancer recurrence is a multidimensional concept that refers to
the uncertainty, concern, and associated dysfunctional behaviour regarding the chance that a
cancer survivor may have to confront another diagnosis of cancer (Howren et al., 2012). It
cannot be reduced or minimized as a “transient affective state manifested upon the conclusion of
treatment” (p. 6) because in reality, fear of cancer recurrence can persist for years post-treatment
(Howren et al., 2012). The survivor’s concern that the malignancy may return after the
completion of treatment is of particular interest since it is related to an increased use of health
care services, as well as poorer QoL for survivors (Stanton et al., 2015). Moreover, the survivor’s
persistent fear of recurrence augments the individual’s risk of diminished mental health that may
be experienced in the form of distress, depression, and anxiety (Cohen et al., 2015; Stanton et al.,
2015).
The extended phase of survivorship is commonly associated with substantial
psychosocial burden (Stanton et al., 2015). Studies have found that individuals commonly
experience an escalation of psychosocial distress after treatment has been completed (Bjordal &
Kaasa, 1995; Lim, Shon, Paek, & Daly, 2014; Stanton et al., 2015). Following completion of
treatment, psychological anxieties of cancer survivors frequently revolve around the uncertainty
of cancer recurrence or progression, disablement, and premature death (Coughlin, 2008; Doyle,
1994). Therefore, an amplified sense of physical vulnerability may lead to somatization and
subsequent misuse of limited healthcare resources (Doyle, 1994; Lim et al., 2014). Moreover,
Misono et al. (2008) found that the “relative increase in suicide risk among persons with cancer
was highest in the first five years after diagnosis with cancer” (p. 4733). Although cancer
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survivors are still at a heightened risk of suicide for approximately 15 years following their
diagnosis when compared to those who had no history of cancer, the risk of suicide among
cancer survivors gradually decreases as they transition into the permanent stage of survivorship
(Misono et al., 2008).
Permanent phase of survivorship. Miller and Shuman (2016) reported that the
permanent phase of survivorship is conceptualized as commencing at the “point of ‘cure’” (p. 2),
where, from a strictly biomedical perspective, “cure” is widely considered to be reached when
the individual has been disease free for five years. As individuals transition into this later
survivorship period, acute somatic morbidities have usually subsided, and the individual has had
time to psychologically process and resolve their disablement experience with HNCa (Stanton et
al., 2015). Nevertheless, survivors may continue to endure the physical and psychosocial
sequelae that were experienced in the extended survival phase continually or periodically
(Stanton et al., 2015). Individuals may experience continued challenges with “reacclimation to
new family or societal roles, coping with the late-effects of therapy, and potentially dealing with
second primary cancers” (Miller & Shuman, 2016, p. 2).
In light of the expansive array of concerns and challenges associated with HNCa and its
treatment, the process through which an individual successfully bridges the gap between sickness
and wellness is of particular interest. Despite all odds, it is possible for positive adaptation to
follow the potentially traumatic and adverse experiences of HNCa (Coughlin, 2008). It follows
that the consideration and conceptualization of this process of positive adaptation may delineate
how survivors may be better equipped to restore wellness after their disabling experiences with
HNCa. Since resilience denotes a dynamic process, characterized by positive adaptation in the
context of significant adversity (Deshields, Heildand, Kracen, & Dua, 2016; Gillespie,
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Charboyer, & Wallis, 2007; Pieters, 2016; Tian & Hong, 2014) it follows that resilience may be
a central variable in understanding how to best prepare HNCa survivors to re-establish overall
well-being.
In essence, how a HNCa survivor perceives their experience with the biopsychosocial
treatment sequelae may potentially be buffered by resilience. As such, owing to the complexity
of the disabling consequences of HNCa, individuals’ capacity to respond resiliently is
particularly relevant in this unique population. Understanding the process of resilience in the
population of HNCa survivors may elucidate how some individuals manage to successfully cope
with the many sequelae of HNCa and its treatment. In understanding the process of resilience in
HNCa survivors, the lessons learned may in turn be applied to help individuals who are
struggling to cope with the disabling impact of surviving HNCa re-establish overall wellness.
Resilience
The term resilience refers to an individual’s ability to transcend an adverse experience
and restore homeostatic functioning in physical, psychological, and social domains of well-being
(Gillespie et al., 2007; Pieters, 2016). Put simply, resilience refers to how individuals respond to
challenges in their lives and, ultimately, how they rebound from such challenges. Resilience may
define how individuals reestablish a sense of balance in their daily living. In essence, an
individual’s adjustment in the wake of adverse circumstances such as, the disablement
experience associated with HNCa, can be conceptualized as the multidimensional process of
resilience. Common defining features of definitions of resilience are outlined in Table 4.
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Table 4
Commonalities Among Definitions of Resilience
•
The capacity of a dynamic system to adapt successfully to disturbances that threaten its function, viability, or development.
•
The ability to avoid deleterious behavioural and physiological changes in response to chronic stress.
•
A process to harness resources to sustain well-being.
•
The capacity to resume positive functioning following adversity.
•
A measure of the degree of vulnerability to shock or disturbance.
•
A person’s ability to adapt successfully to acute stress, trauma, or more chronic forms of adversity.
•
The process of adapting well in the face of adversity, trauma, tragedy, threats, or significant sources of stress.
Note. Retrieved from Supportive Relationships and Active Skill-Building Strengthen the Foundations of Resilience: Working Paper 13, by National Scientific
Council on the Developing Child, 2015, p. 1.

The foundation of resilience is laid during childhood and, as such, consideration of the
development of resilience is warranted to better understand the roots of resilience that adult
HNCa survivors bring with them in their journey with the disease and its treatment. During
childhood, protective experiences and adaptive skills accumulate to counterbalance adversity that
the child may encounter (National Scientific Council on the Developing Child, 2015). This
process of development can be illustrated through the imagery of a balance scale or seesaw,
where positive experiences and developmental variables (e.g., supportive relationships, skill
building opportunities) load the positive outcomes end of the scale and negative experiences and
developmental variables (e.g., exposure to violence, maltreatment, poverty) are stacked onto the
negative outcomes end of the balance scale (National Scientific Council on the Developing
Child, 2015). The development of resilience is illustrated through this balance scale imagery
when, despite a potentially heavy load of negative experiences and variables, the balance scale
still tips in the direction of positive outcomes (National Scientific Council on the Developing
Child, 2015).
When the development of resilience is visualized using this balance scale model, the
representation is not complete without mention of the scale’s fulcrum. The fulcrum is integral in
the determination of which direction an individual’s balance scale will tend to tip. For example,
as is the case with any balance scale, if the fulcrum is positioned closer to one end, it is more
difficult for the scale to tip in that direction (National Scientific Council on the Developing
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Child, 2015). During infancy, the fulcrum is initially positioned based on idiosyncratic
predispositions that reflect underlying genetic variances (National Scientific Council on the
Developing Child, 2015). As the child encounters positive and negative developmental
experiences, the position of the fulcrum may be shifted towards the positive or negative outcome
ends by means of positive or negative experiences, respectively (National Scientific Council on
the Developing Child, 2015). Resilience is evident when developmental variables and
experiences position the fulcrum of the scale to shift the equilibrium so that it is more inclined to
tip in the direction of positive outcomes.
Developmental variables that influence the position of the fulcrum and, thus, the
development of resilience may be categorized into environmental experiences and biological
factors. Resilience is developed through the dynamic interaction between protective experiences
in the child’s social environment and highly responsive biological systems (National Scientific
Council on the Developing Child, 2015). Within the child’s developmental environment, the
presence of a secure and supportive relationship with a parent, caregiver, or other adult is the
single most common variable that predicts the development of resilience (National Scientific
Council on the Developing Child, 2015). A stable relationship contributes to the development of
resilience by providing the child with personalized responsiveness, scaffolding, and protection,
which enable the child to cultivate the key capacities (e.g., executive functioning skills and the
capacity for self-regulation of thought, behaviour, and emotion) required for positive adaptation
to adversity (National Scientific Council on the Developing Child, 2015).
The biological foundation of the development of resilience is rooted in the child’s genes
and developing brain circuitry (National Scientific Council on the Developing Child, 2015). A
child’s gene sequence, gene expression, and neural mechanisms work in combination with his or
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her social environment to ultimately influence the potential for resilience to be developed
(National Scientific Council on the Developing Child, 2015). For instance, a child’s genes dictate
the production of proteins in the brain that are responsible for regulating the child’s reaction to
stress and, thus, have the potential to ameliorate or exaggerate negative outcomes of stress or
adversity (National Scientific Council on the Developing Child, 2015).
Sustained exposure to adversity during childhood can cause long-term changes in the size
and number of neural connections and circuity in brain regions that are responsible for skills
(e.g., behavioural regulation and management of emotional wellness) that are central to the
development of resilience (National Scientific Council on the Developing Child, 2015). Other
key skills that contribute to the development of resilience during childhood, such as the ability to
initiate and sustain social behaviour and form attachment with others, are also influenced by
variation in the activation of brain chemicals like oxytocin and vasopressin (National Scientific
Council on the Developing Child, 2015). When the aforementioned environmental and biological
developmental variables interact in a way that positions the fulcrum of the proverbial resilience
balance scale to shift the equilibrium towards positive outcomes, the development of resilience is
evident.
The foundation of resilience that is laid in childhood has a lasting impact on how adults
respond to adversity, for instance, the experience of HNCa and its treatment. Although factors
that promote the development of resilience may be in place in an individual’s childhood,
resilience is situation-specific; it is not a general trait that is guaranteed in all contexts (National
Scientific Council on the Developing Child, 2015). While data that identify and describe
resilience in populations of HNCa survivors are currently limited, it is undisputed that the
disablement experience associated with HNCa and its treatment is a significant adverse
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experience for survivors. Since resilience is conceptualized as a dynamic process of positive
adaptation in the context of significant adversity, it is justifiable to conceptualize the adverse
experience of HNCa as a viable antecedent for resilience.
Thus, since an individual’s experience with HNCa presents as an event of significant
adversity that crosses physical, psychological, and social domains of functioning (Bornbaum et
al., 2013; Doyle, 1994) it may, elicit a resilient response from a survivor (Pieters, 2016).
Enduring adverse circumstances such as those associated with HNCa, that are perceived by the
individual to be traumatic, may operate as an antecedent to the expression of a resilient response,
which in turn, acts to fundamentally influence an individual’s adaptation to the adverse
circumstances (Gillespie et al., 2007; Markovitz, Schooten, Arntz, & Peters, 2015). That is, the
expression of resilience generally follows a precipitating experience that is perceived by an
individual to be traumatic and threatening to his or her overall well-being. Accordingly,
resilience is not an arbitrary or indiscriminate reaction, but rather, a response elicited by an
experience of significant adversity. For instance, the adverse experience of HNCa may represent
a prerequisite condition for the expression of a resilient response from the cancer survivor. In
turn, the triggered resilient response positions the cancer survivor to respond in a manner that is
more conducive to positive adaptation and, thus, restoration of homeostatic physical,
psychological, and social functioning despite the disabling sequelae of HNCa and its treatment.
A holistic conceptualization of resilience acknowledges that an individual’s resilient
response continues to be shaped by contextual and environmental factors throughout one’s life
span (Gillespie et al., 2007; Tusaie & Dyer, 2004). Tusaie and Dyer (2004) stated that “although
each individual possesses the potential for resilience, an interplay between the individual and
broader environment is responsible for the level of resilience” (p. 3). Interactions between the
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individual and his or her environment are mediated by a resilient response that can enable the
transformation of adverse environmental conditions, into more auspicious conditions (Lim et al.,
2014). In essence, a resilient response reflects an interplay between risk factors and protective
factors at intrapersonal and environmental levels (Gillespie et al., 2007, Tusaie & Dyer, 2004).
Risk factors, or stressors, are characterized by adverse environmental circumstances and
detrimental intrapersonal predispositions that may threaten to exert a negative influence on
physical, psychological, and/or social functioning. In accordance with the conceptualization of a
risk factor, it is apparent that an individual’s disablement experience with HNCa represents a
significant risk factor. More specifically, distinct stressors within an individual’s disablement
experience with HNCa may include the occurrence of concerning symptoms, the diagnostic work
up, and the receipt of the initial diagnosis (Deshields et al., 2016).
A risk factor may also present in the form of compounded chronic strain from multiple
stressors (Tusaie & Dyer, 2004). The chronicity of the stressors associated with HNCa is
apparent upon consideration of the extensive physical and psychosocial long-term and late
effects of treatment (Deshields et al., 2016; Cohen et al., 2015; Llewellyn et al., 2013). For
example, survivors of HNCa commonly encounter considerable challenges to normal functioning
that may include voice and speech deficits, dysphagia, difficulty eating, pain, fatigue, distress,
depression, anxiety, social isolation, role disruption, visible disfigurement, as well as detriments
to body image, self-perception, and emotional expression (Bornbaum et al., 2012; Cohen et al.,
2015; Desheilds et al., 2016; Gritz et al., 1999; Miller & Shuman, 2016; Murphy et al., 2007). As
such, an individual’s experience with HNCa encompasses multiple distinct risk factors that
ultimately unite to generate a significant event of adversity that will require the balancing action
of protective factors to re-establish the individual’s sense of well-being.

37

Protective factors can be conceptualized as “moderators of risk and adversity that
enhance good … outcomes” (Werner, 2000, p. 116). Protective factors ameliorate an individual’s
response to adverse or stressful circumstances to promote more successful adaptation (Werner,
2000). Protective processes involved in the interplay of a resilient response act at an
intrapersonal or environmental level to mitigate the potential threats to an individual’s
functioning and well-being that may emerge in the context of adverse circumstances.
Environmental level protective factors include the presence of social support, while at the
intrapersonal level, protective factors include “adaptive coping strategies, optimism, positive
emotion, self-coherence, and spirituality” (Min et al., 2013, p. 2470).
Protective factors associated with resilience also encompass competencies involved in the
identification or development of resources and strengths in order to navigate stressors and
achieve positive adaptation (Wu et al., 2015). These resources and strengths may be external
agents, in the form of strong social connectedness, “community resources, infrastructure, or
social and cultural factors” (Coughlin, 2008, p. 63), or internal states, in the form of active
coping, cognitive reframing, hopefulness, hardiness, self-efficacy, and cognitive flexibility
(Coughlin, 2008; Deshields et al., 2016; Gillespie et al., 2007, Lim et al., 2014; Markovitz et al.,
2015; Min et al., 2013; Molina et al., 2012).
Garmezy, Masten, and Tellegen (1984) suggested three models that describe the
mechanisms through which the aforementioned protective factors can operate: the compensatory
model, the challenge model, and the immunity model. In the compensatory model, intrapersonal
protective factors and sources of support can counter severe stress or risk factors and, as a result,
risk factors and protective factors combine additively to determine how the individual will fare in
the context of adversity (Garmezy et al., 1984). Garmezy et al. (1984) explained that in the
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challenge model, the presence of risk factors and stress enhances an individual’s competence,
with the provision that the level of stress caused by the risk factors is not excessive. As such, in
the challenge model, a curvilinear relationship characterizes the relation between stress and
competence (Garmezy et al., 1984). In the third mechanism proposed by Garmezy et al. (1984),
the immunity model, a conditional relationship exists between risk factors and protective factors.
In other words, the protective factors temper the negative effect of the risk factors on the
individual’s capacity for successful adaptation, however, in the absence of risk factors, the
protective factors appear to have no perceptible effect (Garmezy et al., 1984). It is worth noting
that the three models are not mutually exclusive, for example, in the pursuit of positive
adaptation the compensatory, challenge, and immunity models may “operate simultaneously or
successively in the adaptive repertoire of a resilient individual” (Werner, 2000, p. 116).
Regardless of the mechanism through which a positive factor may operate, the overall
process of resilience can be conceptualized as a trajectory for healthy adaptation and a
mechanism that protects against psychosocial distress. Despite this, highly resilient individuals
are not immune to negative emotions or maladjustment (Markovitz et al., 2015; Molina et al.,
2012). In other words, Rutter explained that “resilience is conceived as an end product of
buffering processes that do not eliminate risks and stress but that allow the individual to deal
with them effectively” (as cited in Werner, 2000, p. 116). Once again, the value of the
bidirectional interplay between risk and protective factors that is characteristic of resilience is
apparent; resilient individuals still confront risk factors, however, protective factors operate so
that homeostatic functioning may be restored in order to resume overall well-being. In essence,
the intrapersonal and environmental protective factors and the competencies of highly resilient
individuals may allow them to be better equipped to manage negative emotions regardless of the
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precipitating event(s) (Markovitz et al., 2015). It follows that although the confrontation of some
degree of adversity and the associated risk factors are to be expected in life, positive adaptation
in the context of adverse circumstances may be promoted when protective factors are in place to
stimulate the restoration of homeostatic functioning.
If an individual is struggling to restore homeostatic functioning, it is worth noting that the
aforementioned protective factors and the mechanisms through which they operate are amenable
to cultivation and nurturance at any point in time during the lifespan (Deshields et al., 2016;
Gillespie et al., 2007; Pieters, 2016). Therefore, resilience can be viewed as a malleable and
cultivable defense mechanism that enables individuals to adapt positively amid potentially
adverse disablement experiences (Tian & Hong, 2014). It follows that supporting resilience in
HNCa survivors may be a valuable target for adjuvant psychosocial therapies and prophylaxis
(Tian & Hong, 2014). Resilience may explain why some survivors overcome the overwhelming
challenges associated with HNCa, while others fall victim to the disabling consequences of the
disease and its treatment. In essence, it is believed that resilience has the potential to play a
positive role in an individual’s experience with cancer by buffering cancer-related adverse
effects (Wu et al., 2015). Since it is well documented that the adverse effects of HNCa have a
detrimental impact on QoL (Doyle, 2005), it follows that the enhancement of resilience may also
present an opportunity to improve the quality of life of individuals who have been diagnosed and
treated for cancer (Tian & Hong, 2014; Wu et al., 2015). Nevertheless, establishing resilience
enhancing practices in oncological care for HNCa survivors is unlikely unless there are data that
identify and describe the presence of resilience in this population of survivors.
Given the increasing survival rates and growing HNCa survivorship population, survival
can no longer be the primary outcome measure of oncological treatment efficacy (Lawford &
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Eiser, 2001). The resultant shift in the perception of HNCa as a chronic illness instead of a lifethreatening disease (Farrell & Hassey Dow, 1997), necessitates that QoL is categorically distinct
from the rate of biomedically defined survival. In essence, increasing survival rates may equate
to increasing quantity of life, but by no means do they equate to increasing quality of life.
Quality of Life
The global construct of QoL reflects an individual’s overall perception of well-being
(Murphy et al., 2007). By definition, QoL is a multidimensional construct that includes the three
core domains of physical, psychological, and social functioning (Gritz et al., 1999; Murphy et al.,
2007). QoL is a highly-individualized construct that is fluid and changes in different contexts
and over the course of one’s life (Semple et al., 2004). The World Health Organization (WHO)
(1997) provides the most widely cited definition, defining QoL as:
individuals’ perception of their position in life in the context of the culture and value
systems in which they live and in relation to their goals, expectations, standards, and
concerns. It is a broad ranging concept affected in a complex way by the person’s
physical health, psychological state, level of independence, social relationships, personal
beliefs, and their relationship to salient features of their environment. (p. 1)
Beyond the factors mentioned in the WHO’s definition of QoL, individuals’ perceived
QoL is also affected by their idiosyncratic perspective on dimensions that could include
spirituality, sexuality, and intimacy (Gritz et al., 1999). QoL is further influenced by individuals’
intrinsic characteristics including their beliefs, values, and past experiences (Murphy et al.,
2007). The importance of individuals’ subjective perceptions, as well as the influence of
objective contextual aspects of the given set of circumstances is recognized in the WHO’s
definition of QoL (Semple et al., 2004). As such, the objective circumstances surrounding an
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individual’s disablement experience with HNCa in combination with the intrinsic attributes and
subjective perceptions of the individual are likely to idiosyncratically modify QoL.
Accordingly, among the many variables that may influence one’s QoL, health related
issues and the experience of disease are central (Murphy et al., 2007). Doyle (2005) posited that
to “say that the potential effect of a diagnosis of head and neck cancer and the subsequent
treatment of such disease is anything but devastating to one’s QOL is not unreasonable” (p. 5).
Thus, the consideration and assessment of QoL in individuals with HNCa is of notable relevance
since the disablement experience of HNCa is associated with numerous health related issues that
impact domains of functioning, which in turn, profoundly effects one’s QoL (Gritz et al., 1999).
For instance, factors such as “physical, social, cognitive, spiritual, emotional, and role
functioning as well as psychological symptoms and symptoms such as pain, nausea, and
vomiting and fatigue” (Carlson & Bultz, 2004, p. 838) are central issues of the individual’s
disablement experience with HNCa and are also well documented to impact the individual’s
valuation of QoL. More specifically, the experience of HNCa has a severely disabling effect on
each of the three core domains of QoL: dysphagia, xerostomia, and pain contribute to
dysfunction in the physical domain; distress, depression, and visible disfigurement result in
dysfunction in the psychological domain; and detriments to eating, communication, and speech
functions lead to dysfunction in the social domain. Thus, considering the “potential for
morbidity associated with treatment, assessment of quality of life is particularly important with
head and neck cancer patients” (Gritz et al., 1999, p. 352).
Furthermore, since the potential for detriments to HNCa survivors’ perceived QoL is
profound, the assessment of QoL is critical in terms of ensuring optimal provision of care to
address the potential consequences of the disease and its treatment that commonly impact QoL.
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Murphy et al. (2007) suggested attentiveness to patients’ QoL can “(1) facilitate communication
between a physician and their patient, (2) identify problems that have significant impact on QoL,
(3) guide the physician to screen for problems that impact on QoL, and (4) help physicians
prioritize the treatment of problems that develop during treatment” (p. 254). Moreover, QoL
measurement instruments allow patients and health care providers to garner a greater
understanding of the influence of the HNCa disablement experience on physical, psychological,
and social functioning in addition to aiding in decisions related to the modality of treatment that
best fulfills individuals’ biopsychosocial needs (Howren et al., 2012).
Despite numerous studies that explore the QoL of individuals who have been diagnosed
and treated for HNCa, limited data exist on the nature and presence of resilience in this unique
cohort of cancer patients. Furthermore, the potential moderating effect of resilience on the QoL
of individuals who have completed treatment for HNCa is relatively unknown. If the occurrence
of resilience is conceptualized and described within the HNCa survivorship population, the
potential role of resilience in maximizing QoL, while minimizing the impact of HNCa, may be
investigated (Lawford & Eiser, 2001).
Statement of Problem
The upsurge of medical advancements in oncological care has initiated the growth of the
HNCa survivorship population. However, despite delivering a biological cure, advanced medical
treatment often leaves individuals who reach the end of the clinical pathway, far from healthy.
The increasing number of HNCa survivors ultimately equates to an increasing number of
individuals who must face potentially overwhelming biopsychosocial challenges unique to
surviving the disease. Thus, it is of increasing concern that the multitude of challenges
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commonly faced by HNCa survivors frequently remain on the periphery of the focus of
oncological care delivery (Feuerstein, 2007b).
Equally concerning is the fact that the provision of oncological care commonly takes a
reactive stance to individuals’ functional deficits as opposed to working proactively to support
individuals’ journeys through the potential challenges associated with HNCa. In effect,
individuals must be in a functional deficit before they receive attention from the healthcare
system. There is no controversy surrounding the profoundly adverse influence that HNCa and its
treatment has on multiple levels of functioning; yet, functional impairments must be overtly
manifested before individuals with HNCa receive remedial care. In essence, morbidity at the
level of physical, psychological, and social functioning must be firmly manifested before the
individual receives suitable attention from the healthcare system. In spite of the inherently
reactive stance of oncological care delivery, it may be in the best interest of HNCa survivors if
oncological research and care provision adopts a proactive stance that supports survivors before
biopsychosocial dysfunction takes hold. A proactive stance could help individuals to positively
adapt to their disablement experiences with HNCa before negative adaptation can manifest
overtly as psychosocial morbidity that further adds to their disablement.
When oncological care delivers a physical cure for HNCa it is not an indication that the
individuals who have completed the curative treatment are psychologically fit (Bjordal & Kaasa,
1995). For example, psychosocial distress, anxiety, and depression commonly become more
prominent after regular cancer surveillance ends (Lim et al., 2014; Stanton et al., 2015).
Accordingly, the disablement experience of HNCa has a lasting impact on individuals’ physical,
psychological, and social functioning that persists following the completion of treatment. Since
physical, psychological, and social functioning represent the three core domains of individuals’
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perceptions of their QoL, trajectories of recovery often show that HNCa survivors’ QoL is at its
lowest in the period following treatment completion (Howren et al., 2012). When survivors reach
the end of the HNCa clinical pathway they will have overcome the objective physical markers of
HNCa. Unfortunately, the clinical pathway that delivered these survivors a biological cure has
also left them with profound psychosocial dysfunction. The transition into extended survivorship
represents a stage of the cancer continuum in which individuals are most vulnerable to
psychosocial morbidities and are simultaneously receiving minimal care since the supportive
milieu of active treatment has come to an end.
Although a subset of survivors become susceptible to diminished psychosocial health and
QoL that may arise from the extensive sequelae of HNCa and its treatment, evidence suggests
that individuals have the potential to reestablish homeostatic functioning. The recovery
trajectories for HNCa survivors display obvious individual differences that show that some
individuals reestablish homeostatic functioning following treatment completion, while others
continue to experience substantial dysfunction secondary to HNCa and its treatment (Howren et
al., 2012). Accordingly, the question of why some individuals experience extreme impairment
while others have the ability to restore homeostatic levels of functioning in the context of
comparable adverse circumstances is central to the understanding of the survivorship phase of
the HNCa disablement experience (Carver, 1998). A potential answer rests on the notion that
resilience may counter the cumulative impact of the HNCa experience, and act as a “protective
factor against [the development of] psychopathological symptoms” through the period of
survivorship (Markovitz et al., 2015, p. 1644). Tremendous potential may exist for the
minimization of the psychosocial challenges associated with HNCa and its treatment, if
individuals with a potentially higher vulnerability of developing psychosocial morbidity are
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screened and identified before such morbidity can manifest. Markovitz et al. (2015) suggested
that lower levels of resilience may be indicative of higher potential vulnerability to psychosocial
morbidity. Thus, screening for resilience presents as an opportunity for taking a proactive stance
in an attempt to minimize the profound impact of HNCa before it can manifest as psychosocial
morbidity in survivors.
Markovitz et al. (2015) posited that “screening for resilience can lead to early detection
and selection of patients with lower resilience and potentially higher vulnerability to develop
emotional problems” (p. 1644). As such, screening for resilience may present as an initial step in
a proactive approach to support positive adaptation within the context of individuals’
disablement experiences with HNCa. Supporting resilience in those who have been screened and
identified to be less resilient may provide individuals with a fighting chance of reestablishing
homeostatic levels of functioning in psychological and social domains when they reach the end
of the clinical pathway. Research must be conducted to assess the utility of taking a proactive
stance to the psychosocial care of HNCa survivors. Unfortunately, the majority of psychosocial
cancer research has concentrated on the diagnosis and treatment phases of the cancer continuum,
with little focus paid to the extended survivorship period (Stanton et al., 2015). Furthermore,
screening for resilience will not become an established practice in oncological care unless there
are data to substantiate the occurrence of resilience in the HNCa survivorship population. While
data on resilience exist for other oncological populations, to date, little empirical research has
sought to describe the occurrence of resilience within the unique population of individuals who
have completed treatment for HNCa.
Consequently, this research study sought to investigate how resilience may influence
individuals’ QoL in the context of their experience of surviving HNCa. The primary aim of the
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present study centred on the identification of the presence of resilience within the HNCa
survivorship population. This study also aimed to explore the potential for resilience to mitigate,
at least to some extent, the psychosocial sequelae of HNCa, and, thus, the consequential
detriments to QoL. Through an increased understanding of resilience within the HNCa
survivorship population, the role of resilience in minimizing the impact of the disease, while
maximizing survivors’ QoL may be assessed. As such, the specific objectives of the study were
as follows:
1. Identify the presence of resilience in a sample of individuals who have completed
curative treatment for HNCa.
2. Determine if a relationship exists between individuals’ resilience and overall QoL in the
context of their survivorship experience with HNCa.
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CHAPTER 2
Method
Participants
Individuals who had completed treatment for HNCa served as the primary population of
interest for this study. Participants were recruited during their transition into the extended phase

of survivorship that is indicative of the time period following treatment completion. Male and
female survivors who were between 25 and 85 years of age were eligible to participate in this
study. The Department of Otolaryngology - Head and Neck Surgery Clinic at London Health
Sciences Centre, Victoria Campus, London, Ontario, Canada served as the primary location for
participant recruitment.
Demographic information. A total of 39 individuals were initially identified as potential
participants. Of the initially identified individuals, 32 consented to participate. Completed study
packages were received from 31 of the consented individuals, equating to a return rate of 97%.
Of the 31 completed study packages, eight were returned by female participants (25.8%) and 23
by male participants (74.2%). The mean age of the consenting participants was 62.7 years (range
= 39.7 to 82.8 years), with a mean age of 57.6 for the female participants (range = 39.7 to 74.6)
and 64.5 for the male participants (range = 42.5 to 82.8 years). Complete participant
demographic information is presented in Table 5.
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Table 5
Demographic Information of Study Participants
Demographic Variable
Sex
Male
Female
Mean Age
Marital Status
Married
Separated
Divorced
Common-law
Engaged
Single
Dating
Highest Level of Education Achieved
Did not complete High School
Completed High School
Completed College
Undergraduate University Degree
Post-graduate University Degree
Occupational Status
Currently Working – Full-time
Currently Working – Part-time
Volunteer
Retired
Unemployed
Disability Leave
Volunteered and Retired
Household Income
< $25,000
$25,000 - $40,000
$40,001 - $55,000
$55,001 - $70,000
$70,001 - $85,000
> $85,000
Undisclosed

n

%

23
8
62.72

74.2
25.8
N.A.

19
1
1
5
1
3
1

61.4
3.2
3.2
16.1
3.2
9.7
3.2

5
14
7
2
3

16.1
45.2
22.6
6.4
9.7

8
3
1
16
1
1
1

25.8
9.7
3.2
51.7
3.2
3.2
3.2

3
2
4
4
3
7
8

9.7
6.4
12.9
12.9
9.7
22.6
25.8

Site and clinical stage of cancer and method of treatment. The participants had
completed varied treatment modalities for malignancies in various primary sites within the head
and neck region. The predominant diagnosis among participants was oral cavity cancer (n = 19),
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followed by laryngeal cancer (n = 8). The majority of the participants’ tumours were clinically
staged as T1N0 (n=11). Of the 31 participants, 14 received surgery as the sole treatment modality,
nine received surgery and radiation therapy, and five received surgery, radiation therapy, and
chemotherapy. Table 6 presents a summary of the primary sites of cancer origin, the clinical
stage of the tumours and the distribution of treatment modalities employed in the management of
the participants’ HNCa. The length of time elapsed since the participants’ diagnosis of HNCa
ranged from seven to 58 months (mean = 25.7). The time elapsed since treatment completion
ranged from one to 59 months (mean = 21.9). The distribution of the time since diagnosis and
treatment completion among the participants are presented in Table 7.
Table 6
Site and Clinical Stage of Cancer and Modality of Treatment
Variable
Site of Cancer
Oral Cavity
Larynx
Nasopharynx
Lymph Nodes
Larynx and Thyroid
Oral Cavity and Thyroid
Clinical Stage of Cancer
Carcinoma in situ
T1N0
T1N1
T2N0
T2N1
T2N2
T3N0
T3N2
T4N0
T4N1
TXN2
Modality of Treatment
Surgery
Radiation Therapy
Chemoradiation Therapy
Surgery and Radiation Therapy
Surgery, Radiation Therapy, and Chemotherapy

n

%

19
8
1
1
1
1

61.4
25.8
3.2
3.2
3.2
3.2

2
11
1
2
1
3
3
2
3
2
1

6.4
35.7
3.2
6.4
3.2
9.7
9.7
6.4
9.7
6.4
3.2

14
2
1
9
5

45.2
6.4
3.2
29.1
16.1

50

Table 7
Time Since Diagnosis and Treatment Completion
Variable
Time Since Diagnosis
<10 months
10-19 months
20-29 months
30-39 months
40-49 months
50> months
Time Since Treatment Completion
<10 months
10-19 months
20-29 months
30-39 months
40-49 months
50> months

n

%

5
8
6
7
1
4

16.1
25.8
19.3
22.7
3.2
12.9

8
7
8
4
2
2

25.8
22.7
25.8
12.9
6.4
6.4

Inclusion criteria. The diagnosis of HNCa, as well as the completion of treatment was
required for participant inclusion in this investigation. Accordingly, to participate, individuals
were required to be in the extended phase of survivorship, defined by tasks of reassimilation and
reentry following treatment completion (Miller & Shuman, 2016). Participation was limited to
individuals that were a minimum of one month, but no more than five years beyond the end of
curative treatment, irrespective of treatment modality. Self-reported good general health
exclusive of their diagnosis of HNCa was required. Inclusion criteria further stipulated a
minimum age of 25 years and maximum age of 85 years for participation. All participants were
required to display adequate English proficiency at the time of recruitment and formal consent.
Exclusion criteria. Individuals were excluded from participation in this study if they had
received a previous diagnosis of non-HNCa regardless of its location. If an individual had
experienced a recurrence of HNCa they were also excluded. Individuals that had been diagnosed
and treated for skin cancer (basal cell, squamous cell, or melanoma) in the head and neck region
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were not permitted to participate. Exclusion from participation was also a result of treatment that
was ongoing. If completion of curative treatment occurred less than one month or more than five
years prior to participation, it excluded individuals from being recruited. If the individual was
younger than 25 years of age, or older than 85 years of age, participation was prohibited. Finally,
individuals were excluded from participation if their English proficiency was too low to provide
informed consent and complete research tasks required for study involvement.
Procedure
Data collection. This research study was a cross-sectional, self-report, survey design. In
accordance with the aforementioned inclusion and exclusion criteria, patients’ charts were
reviewed to assess participation eligibility. First contact with eligible potential participants was
made through their otolaryngologist/surgeon during routine follow-up visits that occurred after
the completion of treatment. At that time, the individual was informed of the general purpose of
the study by their otolaryngologist. The potential participant only made contact with the primary
researcher if continued interest in participation was indicated by the individual. As such, the
primary population of interest may be considered a sample of convenience, since their
accessibility to the researcher was granted by the partnership with the Department of
Otolaryngology – Head and Neck Surgery Clinic. Consecutive sampling was used to recruit the
participants.
Upon introduction to the researcher, comprehensive details of study participation were
conveyed through a written letter of information, in conjunction with a verbal explanation.
Individuals who indicated sustained interest in study involvement then received the package of
study materials. At this point, all participants gave informed consent in compliance with ethical
approval granted by the Western University Health Sciences Ethics Board (REB Approval #
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108785). Upon completion of informed consent, a coded participant number known only to the
investigators was assigned to each participant. The participant codes ensured that data gathered
from participants were free of any personal identifiers that may have linked individuals to their
respective data.
Enclosed in the package of study materials was: the formal letter of information and
consent, a demographic information inquiry form, one validated, self-report questionnaire
pertaining to the collection of resiliency data, two validated, self-report questionnaires pertaining
to QoL data collection, and a contact list for local psychological support services and
organizations that offer support to individuals that have experienced the disablement associated
with HNCa. The package of study materials was either filled out on the spot, or in some
instances, taken away and returned by mail at a later date. A prepaid and pre-addressed envelope
for the return of the package of study materials was provided if the participant elected to
complete the package of study materials off site. The aforementioned stipulations served as the
grounds for formal ethical approval, which was granted by the Western University Health
Sciences Ethics Board before study commencement (REB #108785); copies of the initial
approval and amendment approval for this study are provided in Appendices A and B,
respectively.
Measurement instruments. This study collected data to identify the presence of
resilience and its potential protective role in buffering the adverse effect of HNCa on QoL by
employing three validated, self-report measurement instruments. To gather data pertaining to
resilience, the Connor-Davidson Resilience Scale (CD-RISC) was utilized. The European
Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30), supplemented by The European Organisation for Research and Treatment of Cancer
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Head and Neck Cancer Module (EORTC QLQ-H&N35) were administered to gather the QoL
data.
The Connor-Davidson Resilience Scale (CD-RISC). The Connor-Davidson Resilience
Scale is a 25-item self-report measure of resilience. This measurement instrument distinguishes
between individuals with higher and lower levels of resilience (Ahern, Kiehl, Sole, & Byers,
2006). Each item is rated on a 5-point Likert scale, ranging from zero to four. For each item,
participants indicate the degree to which the item prompt is true within the context of their life.
For example, the prompt for item one states “I am able to adapt when changes occur,” and the
participant responds by indicating that this prompt is “not true at all” with a score of zero, “rarely
true” with a score of one, “sometimes true” with a score of two, “often true” with a score of
three, and “true nearly all the time” with a score of four. The CD-RISC is scored by a simple
summation of the responses for the 25 items (Davidson & Connor, 2016). As such, zero is the
minimum score and 100 is the maximum score, where higher scores reflect higher levels of
resilience (Davidson & Connor, 2016). A clinically significant score or threshold has not yet
been established and, thus, interpretation of the CD-RISC total score remains a subjective
evaluation of the summation of the participants responses to the 25-items. The CD-RISC
“demonstrates sound psychometric properties, with good internal consistency and test-retest
reliability, [and] exhibits validity relative to other measures of stress and hardiness” (Connor &
Davidson, 2003, p. 81).
The CD-RISC was developed for use within a wide selection of populations including
primary care outpatients (Tusaie & Dyer, 2004); however, this measure has not been explicitly
developed for application within HNCa survivors. Despite this, Connor and Davidson (2003)
suggest that the scale can be used in the investigation of positive adaptation in the context of
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adverse circumstances, and as a tool for screening individuals who may be at higher risk of
negative adaptation. As discussed previously, a survivor’s disablement experience with HNCa is
commonly characterized by a succession of traumatic events that are justifiably representative of
adverse circumstances (Molina et al., 2012). For example, individuals who have faced the
disablement experience of HNCa are subjected to a progression of adverse events that begin at
the onset of concerning symptoms and the initial receipt of diagnosis, and continue even after
treatment completion in the form of profound detriments to numerous domains of functioning
that may involve speech deficits, dysphagia, pain, fatigue, depression, visible disfigurement, and
social isolation. As such, individuals that have received treatment for HNCa may be at a
heightened risk of negative adaptation in the domains of psychological, social, and physical
functioning (Doyle, 1994). Accordingly, application of the CD-RISC to the population of HNCa
survivors holds justifiable utility.
The European Organisation for the Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30). The European Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Study Group developed the EORTC QLQ-C30 as a cancer
specific QoL measurement instrument. The QLQ-C30 is a 30-item questionnaire that is simple
and brief to complete, thereby enhancing its use as a self-report measurement instrument
(Aaronson et al., 1993). The items in this core questionnaire cover concerns relevant to cancer
patients irrespective of the site of disease (Bjordal et al., 1994) and are representative of the
multidimensionality of the construct of QoL (Aaronson et al., 1993). The 30 items are
categorized into five Functioning Scales (Physical, Role, Cognitive, Emotional, and Social),
three Symptom Scales (Fatigue, Pain, and Emesis), six Single Item Measures (Dyspnea,
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Insomnia, Appetite Loss, Constipation, Diarrhea, and Financial Difficulties), and a Global Health
Status/QoL Scale (Aaronson et al., 1993; Bjordal et al., 1994).
The first 28 items are related to the participant’s perceived functioning and experience of
various symptoms relevant to their experience with cancer. Participants indicate their responses
to these items on a four-point Likert scale coded with four response categories: “not at all” (1),
“a little” (2), “quite a bit” (3), and “very much” (4) (Aaronson et al., 1993). QLQ-C30 items 29
and 30 seek information regarding participants’ perceptions of their global health and overall
QoL, respectively, and are rated on Likert scales that range from one to seven, where a response
of one indicates “very poor” overall health or QoL and a response of seven indicates “excellent”
overall health or QoL. Raw scores for each scale are generated through a calculation of the
average of the items that contribute to the scale (Fayers et al., 2001). The raw scores for each of
the 14 scales are then standardized through linear transformation so each scale score has the
same range of 0 to 100 (Fayers et al., 2001). Following linear transformation, a high score on a
scale of functioning is indicative of a high or healthy (“better”) level of functioning (Aaronson et
al., 1993). Similarly, a transformed scale score on the Global Health Status/QoL Scale suggests a
high health status or QoL (Aaronson et al., 1993). Conversely, a high score for a symptom scale
or single item measure indicates a high level of symptomology or challenge (“worse” level of
symptoms) (Aaronson et al., 1993). As such, the transformed scores for the various scales require
careful interpretation. The QLQ-C30 has been validated in diverse cancer populations and has
been shown to have strong psychometric properties (Sherman et al., 2000).
The European Organisation for Research and Treatment of Cancer Head and Neck
Cancer Module (EORTC QLQ-H&N35). The EORTC QLQ-H&N35 is a “head and neck cancer
specific questionnaire module designed to be used in quality of life assessments before, during,
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and after radiotherapy and surgery, with or without combinations with chemotherapy” (Bjordal
et al., 1994, p. 879). It is a 35-item self-report measurement instrument intended to be used as a
supplement to the core QLQ-C30 questionnaire. The items of the QLQ-H&N35 concern issues
associated with the disease and treatment related symptoms and side effects, social function, and
sexuality that are concomitant with the HNCa disablement experience. The items are separated
into seven multi-item scales that address pain, swallowing, problems with senses, problems with
speech, trouble with social eating, trouble with social contact, and issues pertaining to sexuality
(Aaronson et al., 1993). The QLQ-H&N35 also contains 11 single items that pertain to issues
with teeth, opening the mouth, dry mouth, sticky saliva, coughing, feeling ill, use of pain killers,
use of nutritional supplements, use of a feeding tube, weight loss, and weight gain (Aaronson et
al., 1993).
Participants respond to the first 30 items using the same four-point scale that is utilized in
the QLQ-C30. The final five items are scored on a two-point scale coded with two response
categories: “yes” (1) and “no” (2) (Aaronson et al., 1993). The raw scores are then transformed
using the same method of linear transformation used in the QLQ-C30 core questionnaire (Fayers
et al., 2001). Once transformed, higher scores for all scales and single items indicate a higher
perceived level of challenge or problems in the scale’s content area (Aaronson et al., 1993).
Strong psychometric properties have been established for this measurement instrument (Bjordal
et al., 1994). This EORTC site specific module was completed concurrently with the core
questionnaire in this study to garner a more thorough valuation of participants’ perceived QoL
and to offer supplementary data pertinent to assessing QoL in individuals with HNCa (Aaronson
et al., 1993).
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Data analysis. Upon receipt of completed packages of study materials, the standard
scoring procedures for each measurement instrument were used to calculate participants’ scores
for each of the three utilized questionnaires. While the CD-RISC is scored through simple
summation of the responses to the 25 items, the scoring procedures for the QLQ-C30 and QLQH&N35 are more complex and are summarized in Appendix H. The resultant scores obtained
from the CD-RISC, QLQ-C30, and QLQ-H&N35 were then recorded.
SPSS Statistics Software was used in the statistical analyses of the data. Descriptive
statistics were calculated: measures of central tendency were calculated to summarize the typical
distribution of the data collected from the CD-RISC, QLQ-C30, and QLQ-H&N35 and measures
of dispersion were calculated to describe the variability around the measures of central tendency.
Correlational analysis using SPSS Statistics software was used to determine potential statistically
significant relationships between the scores gathered from the CD-RISC, QLQ-C30, and QLQH&N35. Statistical analysis also included nonparametric Mann-Whitney U-tests to compare
potential differences in male and female participants’ CD-RISC total scores and Global Health
Status/QoL scale scores since the data were not normally distributed. Additionally, observational
analyses were completed to garner anecdotal descriptions of trends between applicable
demographic variables and scores for resilience and QoL.
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CHAPTER 3
Results
In the sections to follow, the results of this study will be presented. To begin, participant
response rates were examined and descriptive statistics for the CD-RISC, EORTC QLQ-C30,
and EORTC QLQ-H&N35 were calculated. Correlational analysis of the three measurement
instruments was completed, as well as observational analysis of variables including sex, age, site
of cancer, clinical stage of cancer, treatment modality, time since diagnosis, and time since
treatment completion.
Response Rates
Thirty-nine individuals were initially identified as potential participants. Of these, 32
consented to participate. Those who chose not to participate predominantly cited time restraints
as the primary reason. All but one of the consented participants completed the package of study
materials on site (n=30); one completed the package off site and returned it by mail. Although
one other individual agreed to complete the package off site, it was never returned. Thus, overall
97% (n = 31) of the consented participants completed the package of study materials.
Descriptive Statistics
Connor-Davidson Resilience Scale (CD-RISC). The mean, median, and mode, as well
as the standard deviation and range were calculated for the raw score of each of the 25 items of
the CD-RISC. After total scores were calculated through the standard process of simple
summation of the participants’ responses to the 25 items, measures of central tendency and
dispersion for the total scores were generated. These data are summarized in Table 8. Of the 25
items, the mean was highest for item 25 (“I take pride in my achievements.”) and lowest for item
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3 (“When there are no clear solutions to my problems, sometimes fate or God can help.”). The
highest standard deviation corresponded to item 3, while the lowest standard deviation was found
for item 10 (“I give my best effort no matter what the outcome may be.”).
One participant failed to respond to items 7 and 15. When responses are missing from the
CD-RISC, the scale is still considered valid when a minimum of 75% of the measure is
completed (a minimum of 19 items). As such, the incomplete measure was considered valid and
these data were included in analyses. In accordance with the prescribed instructions for the
management of missing responses on the CD-RISC, the missing responses were replaced with
the rounded mean score for the other items on the scale (mean = 3) for calculations pertaining to
total scores. The calculations for measures of central tendency and dispersion for items 7 and 15
were made excluding each respective item’s missing response and, as such, the sample value was
adjusted accordingly (N = 30 for item 7 and 15).
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Table 8
Measures of Central Tendency and Dispersion for CD-RISC
Item Number
N
Mean
Median
Mode
Q1
31
3.29
4
4 (17)
Q2
31
3.16
4
4 (19)
Q3
31
2.23
2
4 (12)
Q4
31
3.35
4
4 (18)
Q5
31
3.35
4
4 (18)
Q6
31
3.26
4
4 (20)
Q7
30
2.93
3
4 (12)
Q8
31
3.45
4
4 (17)
Q9
31
2.68
3
4 (13)
Q10
31
3.48
4
4 (17)
Q11
31
3.45
4
4 (18)
Q12
31
3.26
3
3/4* (14)
Q13
31
3.23
4
4 (17)
Q14
31
3.13
3
4 (14)
Q15
30
3.17
3.5
4 (15)
Q16
31
3.10
3
4 (15)
Q17
31
3.03
3
4 (13)
Q18
31
3.06
3
4 (15)
Q19
31
3.13
4
4 (16)
Q20
31
3.10
3
3 (13)
Q21
31
3.23
3
4 (15)
Q22
31
3.42
4
4 (19)
Q23
31
2.90
3
4 (13)
Q24
31
3.35
4
4 (16)
Q25
31
3.52
4
4 (20)
Total Score
31
79.26
85
88/96* (3)
*Multiple modes exist, both are presented.
Parenthetical values present the frequencies.

Range
3
4
4
4
4
4
4
2
4
2
4
4
4
4
4
4
4
4
4
3
4
4
4
4
4
90

SD
0.94
1.37
1.69
0.95
0.95
1.26
1.23
0.68
1.42
0.63
0.85
0.93
1.12
1.02
1.12
1.08
1.08
1.32
1.09
0.83
1.06
0.92
1.27
0.88
0.85
17.69

European Organisation for the Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30). The mean, median, mode, range, and standard deviation
were also calculated for each of the 30 questions on the QLQ-C30 (see Table 9), as well as for
the five Functioning Scales (Physical, Role, Cognitive, Emotional, and Social), three Symptom
Scales (Fatigue, Pain, and Emesis), six Single Item Measures (Dyspnea, Insomnia, Appetite
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Loss, Constipation, Diarrhea, and Financial Difficulties), and the Global Health Status/QoL
Scale (see Table 10). The values that appear in Table 10 represent the scores for each scale and,
thus, values are the result of raw score calculations followed by linear transformation to generate
scores that all range from 0 to 100 (see Appendix H for General Principles of Scoring the QLQC30). It is worth noting that higher scores for the scales of functioning and Global Health
Status/QoL reflect better levels of functioning and QoL, respectively, while higher scores for the
Symptom Scales and Single Item Measures indicate greater perceived challenge (Aaronson et al.,
1993).
Among the items that contribute to the Functioning Scales, Symptoms Scales, and Single
Item Measures (questions 1 to 28), the highest mean score corresponded to question 11 (“Have
you had trouble sleeping?”). Question 15 (“Have you vomited?”) had the lowest mean score. The
standard deviation was found to be greatest for question 11 (“Have you had trouble sleeping?”)
and the least for question 15 (“Have you vomited?”). Questions 29 and 30 were not included in
the analysis of the first 28 questions since they are scored using seven-point Likert scales not the
four-point Likert scales used for questions 1 to 28. Among the two questions that contribute to
the Global Health Status/QoL Scale, the higher mean score corresponded to question 29 (“How
would you rate your overall health during the past week?”). Question 30 (“How would you rate
your overall quality of life during the past week?”) had a greater standard deviation when
compared with item 29.
Among the five Functioning Scales, the Role Functioning Scale was found to have the
highest mean, while the Emotional and Social Functioning Scales had lowest means. The
greatest standard deviation for the Functional Scales was found for the Social Functioning Scale,
while the lowest was found for the Physical Functioning Scale. For the Symptom Scales and
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Single Item Measures, the Insomnia Single Item Measure and the Nausea and Vomiting
Symptom Scale had the highest and lowest means and standard deviations, respectively.

Table 9
Measures of Central Tendency and Dispersion for Items of EORTC QLQ-C30
Item Number
N
Mean
Median
Mode
Range
Q1
31
1.65
1
1 (16)
2
Q2
31
1.55
1
1 (18)
2
Q3
31
1.06
1
1 (29)
1
Q4
31
1.03
1
1 (30)
1
Q5
31
1.03
1
1 (30)
1
Q6
31
1.23
1
1 (26)
2
Q7
31
1.26
1
1 (25)
2
Q8
31
1.39
1
1 (21)
3
Q9
31
1.48
1
1 (20)
2
Q10
31
1.55
1
1 (18)
3
Q11
31
1.74
1
1 (16)
3
Q12
31
1.52
1
1 (17)
3
Q13
31
1.26
1
1 (23)
1
Q14
31
1.16
1
1 (26)
1
Q15
31
1.00
1
1 (31)
0
Q16
31
1.29
1
1 (25)
3
Q17
31
1.10
1
1 (28)
1
Q18
31
1.65
2
1 (15)
3
Q19
31
1.42
1
1 (21)
2
Q20
31
1.13
1
1 (27)
1
Q21
31
1.42
1
1 (20)
3
Q22
31
1.45
1
1 (21)
3
Q23
31
1.35
1
1 (23)
3
Q24
31
1.45
1
1 (22)
3
Q25
31
1.39
1
1 (20)
2
Q26
31
1.39
1
1 (23)
3
Q27
31
1.45
1
1 (21)
3
Q28
31
1.10
1
1 (29)
2
Q29
31
5.61
6
7 (11)
5
Q30
31
5.58
6
7 (12)
5
Parenthetical values present the frequencies.

SD
0.76
0.72
0.25
0.18
0.18
0.56
0.58
0.67
0.72
0.77
0.93
0.68
0.45
0.37
0.00
0.69
0.30
0.76
0.67
0.34
0.67
0.77
0.71
0.85
0.56
0.80
0.77
0.40
1.36
1.57
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Table 10
Measures of Central Tendency and Dispersion for EORTC QLQ-C30 Scale scores
Scale
N
Mean
Median
Mode
Range
Global health status/QoL
Scale
31
76.61
83.33
100.00 (9)
83.33
Functional Scales
Physical Functioning
31
91.18
93.33
100.00 (15)
33.33
Role Functioning
31
91.94
100.00
100.00 (23)
50.00
Emotional Functioning
31
86.02
91.67
100.00 (15)
75.00
Cognitive Functioning
31
91.40
100.00
100.00 (19)
50.00
Social Functioning
31
86.02
100.00
100.00 (21)
100.00
Symptom Scales
Fatigue
31
18.99
11.11
0.00 (13)
66.67
Nausea & Vomiting
31
2.69
0.00
0.00 (26)
16.67
Pain
31
15.05
0.00
0.00 (19)
66.67
Single Item Measures
Dyspnea
31
12.90
0.00
0.00 (21)
100.00
Insomnia
31
24.73
0.00
0.00 (16)
100.00
Appetite Loss
31
8.60
0.00
0.00 (23)
33.33
Constipation
31
9.68
0.00
0.00 (25)
100.00
Diarrhea
31
3.23
0.00
0.00 (28)
33.33
Financial Difficulties
31
3.23
0.00
0.00 (29)
66.67
Parenthetical values present the frequencies.

SD
22.92
9.95
14.83
19.99
12.82
24.38
19.92
6.23
22.51
22.24
30.99
14.83
23.08
10.02
13.21

European Organisation for the Research and Treatment of Cancer Head and Neck
Cancer Module (EORTC QLQ-H&N35). Table 11 displays the measures of central tendency
and dispersion for the 35 items of the QLQ-H&N35. The highest mean was found for question
11 (“Have you had a dry mouth?”), while the lowest mean response was observed for question
33 (“Have you used a feeding tube?”). The greatest standard deviation was found for question 9
(“Have you had problems with your teeth?”), while the least was found for question 33 (“Have
you used a feeding tube?”).
The QLQ-H&N35 is scored using the same principles as the QLQ-C30, thus, linear
transformation generates scale scores so the seven Symptom Scales and 11 Single Item Measures
have the same potential range. For all scales of the QLQ-H&N35, a higher score reflects greater
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perceived challenge (Aaronson et al., 1993). Measures of central tendency and dispersion for
QLQ-H&N35 scale scores are shown in Table 12. The highest mean corresponded to the Dry
Mouth Single Item Measure, while the lowest mean corresponded to the Feeding Tube Single
Item Measure. The standard deviation was greatest for the Nutritional Supplements Single Item
Measure and lowest for the Swallowing Symptom Scale.
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Table 11
Measures of Central Tendency and Dispersion for Items of EORTC QLQ-H&N35
Item Number
N
Mean
Median
Mode
Range
Q1
31
1.48
1
1 (22)
3
Q2
31
1.32
1
1 (23)
2
Q3
31
1.52
1
1 (21)
3
Q4
31
1.23
1
1 (24)
1
Q5
31
1.19
1
1 (26)
2
Q6
31
1.16
1
1 (29)
3
Q7
31
1.58
1
1 (20)
3
Q8
31
1.19
1
1 (27)
3
Q9
31
1.84
1
1 (18)
3
Q10
31
1.42
1
1 (24)
3
Q11
31
2.32
2
2 (12)
3
Q12
31
1.94
2
1 (15)
3
Q13
31
1.32
1
1 (24)
3
Q14
31
1.61
1
1 (18)
3
Q15
31
1.81
2
2 (18)
3
Q16
31
1.55
1
1 (19)
3
Q17
31
1.26
1
1 (25)
2
Q18
31
1.26
1
1 (25)
2
Q19
31
1.52
1
1 (20)
3
Q20
31
1.42
1
1 (24)
3
Q21
31
1.55
1
1 (23)
3
Q22
31
1.55
1
1 (21)
3
Q23
31
1.55
1
1 (19)
3
Q24
31
1.48
1
1 (21)
3
Q25
31
1.29
1
1 (25)
3
Q26
31
1.35
1
1 (23)
3
Q27
31
1.26
1
1 (26)
3
Q28
31
1.23
1
1 (26)
3
Q29
31
1.65
1
1 (18)
3
Q30
31
1.61
1
1 (18)
3
Q31
31
1.32
1
1 (21)
1
Q32
31
1.35
1
1 (20)
1
Q33
31
1.03
1
1 (30)
1
Q34
31
1.23
1
1 (24)
1
Q35
31
1.26
1
1 (23)
1
Parenthetical values present the frequencies.

SD
0.85
0.60
0.89
0.43
0.48
0.64
0.96
0.60
1.13
0.89
1.01
1.09
0.70
0.88
0.70
0.85
0.58
0.58
0.85
0.89
1.03
0.93
0.81
0.81
0.69
0.71
0.68
0.62
0.95
0.92
0.48
0.49
0.18
0.43
0.45
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Table 12
Measures of Central Tendency and Dispersion for EORTC QLQ-H&N35 Scale scores
Scale
N
Mean
Median
Mode
Range
SD
Symptom Scales
Pain Scale
31
12.90
0.00
0.00 (18)
66.67
19.58
Swallowing Scale
31
9.41
0.00
0.00 (18)
58.33
15.92
Senses Scale
31
15.59
16.67
0.00 (14)
66.67
18.73
Speech Scale
31
17.56
11.11
0.00 (13)
77.78
22.37
Social Eating Scale
31
16.94
0.00
0.00 (18)
100.00
26.74
Social Contact Scale
31
9.25
0.00
0.00 (22)
80.00
18.27
Sexuality Scale
31
20.97
0.00
0.00 (16)
100.00
30.11
Single Items
Teeth
31
27.96
0.00
0.00 (18)
100.00
37.61
Opening Mouth
31
13.98
0.00
0.00 (24)
100.00
29.53
Dry Mouth
31
44.09
33.33
33.33 (12) 100.00
33.76
Sticky Saliva
31
31.18
33.33
0.00 (15)
100.00
36.45
Coughing
31
26.88
33.33
33.33 (18) 100.00
23.44
Felt Ill
31
8.60
0.00
0.00 (25)
66.67
19.18
Pain Killers
31
32.26
0.00
0.00 (21)
100.00
47.52
Nutritional Supplements
31
35.48
0.00
0.00 (20)
100.00
48.64
Feeding Tube
31
3.23
0.00
0.00 (30)
100.00
17.96
Weight Loss
31
22.58
0.00
0.00 (24)
100.00
42.50
Weight Gain
31
25.81
0.00
0.00 (23)
100.00
44.48
Parenthetical values present the frequencies.

Correlational Analyses
CD-RISC and EORTC QLQ-C30. Correlational analysis was initially performed
between the CD-RISC total scores and the scale scores for the Global Health Status/QoL Scale,
Functional Scales, Symptom Scales, and Single Item Measures on the QLQ-C30 (see Table 13).
As can be seen in Table 13, moderate to strong relationships were found between several of the
variables.
A positive and strong statistically significant relationship was found between the CDRISC total scores and the Global Health Status/QoL scale scores (r=0.615, p<0.01); this

67

relationship is displayed graphically in Figure 1. The strongest statistically significant correlation
between the CD-RISC total scores and the Functional Scales of the QLQ-C30 was identified
between the CD-RISC total scores and the Social Functioning Scale (r=0.669, p<0.01).
Comparison of the five Functional Scales with the Global Health Status/QoL scale scores
indicated that the strongest statistically significant correlation existed between Global Health
Status/QoL and Emotional Functioning (r=0.652, p<0.01). Among the Symptom Scales and
Single Item Measures of the QLQ-C30 the most significant correlation to the CD-RISC was
found for the Dyspnea Single Item Measure (r=-0.638, p<0.01). The strongest correlation was
found between the Global Health Status/QoL scale scores and the Pain Scale (r=-0.560, p<0.01)
when just the Symptom Scales and Single Item Measures were considered.

Figure 1. Comparison of Global Health Status/QoL scale scores and CD-RISC total scores.
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CD-RISC, Global Health Status/QoL Scale, and EORTC QLQ-H&N35. CD-RISC
total scores were also compared with scores for the Symptom Scales and Single Item Measures
on the QLQ-H&N35. Table 14 shows the resulting correlational matrix. The strongest
statistically significant correlation was found between the CD-RISC total score and the Social
Contact Scale (r=-0.663, p<0.01). Finally, the Global Health Status/QoL scale scores from the
QLQ-C30 and the Symptom Scales and Single Item Measures scores from the QLQ-H&N35
were compared to investigate potential relationships (see Table 14). The Nutritional Supplements
Single Item scale scores from the QLQ-H&N35 had the strongest correlation with the Global
Health Status/QoL scale scores from the QLQ C-30 (r=-0.676, p<0.01).
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Table 13
Correlational Matrix: Comparing Total CD-RISC Scores and EORTC QLQ-C30 Scale scores
CDRISC
G
HS/QoL
Phys FS

CDRISC

G
HS/QoL

Phys
FS

Role
FS

Emot
FS

Cogn
FS

Soci
FS

Fati
SS

Naus
SS

Pain
SS

Dysp
SI

Inso
SI

Appe
SI

Cons
SI

Diar
SI

Fina
SI

1

.615**

.303

.161

.442*

.157

.669**

-.320

-.445*

-.604**

-.638**

-.245

.169

-.006

-.042

-.146

1

.503**

.448*

.652**

.380*

.555**

-.529**

-.291

-.560**

-.387*

-.501**

.067

-.048

-.144

-.171

1

.481**

.430*

.460**

.498**

-.485**

-.322

-430*

-.574**

-.519**

-.222

-.229

-.077

-.171

1

.669**

.597**

.421*

-.593**

-.259

-.456**

-.348

-.478**

-.011

.019

-.068

-.525**

1

.400*

.735**

-.667**

-.394*

-.700**

-.372*

-.664**

.044

-.239

-.322

-.279

1

.373*

-.403*

-.512**

-.242

-.312

-.146

-.280

.040

-.065

-.706**

1

-.388*

-.537**

-.717**

-.647**

-.434*

-.169

-.278

-.264

-.258

1

.371*

.759**

.376*

.794**

.055

.016

.240

.276

1

.494**

.543**

.316

.343

.071

.450*

.566**

1

.487**

.696**

.098

.138

.435*

.205

1

.328

.101

.037

-.027

.232

1

.166

.379*

.331

.070

1

.398*

.306

.232

1

.501**

-.106

1

-.081

Role FS
Emot
FS
Cogn
FS
Soci
FS
Fati
SS
Naus
SS
Pain
SS
Dysp
SI
Inso
SI
Appe
SI
Cons
SI
Diar
SI
Fina
SI

* p < .05 (2-tailed)
** p < .01 (2-tailed)

1
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Table 14
Correlational Matrix: Comparing Total CD-RISC Scores, Global Health Status/QoL and EORTC QLQ-H&N35 Scale scores
CDRISC
G
HS/Q
Pain
SS
Swal
SS
Sens
SS
Spee
SS
SoEa
SS
SoCo
SS
Sexu
SS
Teet
SI
OpMo
SI
DrMo
SI
StSa
SI
Coug
SI
FeIl
SI
PaKi
SI
NuSu
SI
FeTu
SI
WeLo
SI
WeGa
SI

CDRISC

G
HS/Q

Pain
SS

Swal
SS

Sens
SS

Spee
SS

SoEa
SS

SoCo
SS

Sexu
SS

Teet
SI

OpMo
SI

DrMo
SI

StSa
SI

Coug
SI

FeIl
SI

PaKi
SI

NuSu
SI

FeTu
SI

WeLo
SI

WeGa
SI

1

.615**

.154

-.323

.038

.510**

-.429*

.663**

-.443*

.567**

-.205

-.157

-.061

-.076

-.347

-.419*

-.375*

-.108

.152

-.043

1

.321

-.386*

-.017

.503**

.432**

.475**

-.393*

.613**

-.335

-.131

-.162

-.325

.475**

.458**

.676**

-.148

.018

-.260

1

.734**

.367*

.431*

.762**

.344

.311

.638**

.670**

.511**

.689**

.409*

.607**

.165

.407*

.194

.406*

.211

1

.485**

.344

.804**

.404*

.299

.752**

.597**

.322

.595**

.267

.545**

.136

.523**

.473**

.250

.234

1

.165

.287

.171

.041

.254

.262

-.010

.431*

.195

-.025

-.334

.165

.341

-.038

.168

1

.539**

.665**

.443*

.527**

.420*

.396*

.336

.223

.471**

.286

.361*

.039

.036

.125

1

.631**

.533**

.756**

.616**

.489**

.495**

.416*

.789**

.299

.462**

.172

.434*

.017

1

.578**

.549**

.302

.206

.131

.075

.421*

.285

.419*

.177

.123

.134

1

.463**

.263

.336

.194

.119

.479**

.327

.385*

-.027

.095

.122

1

.637**

.339

.532**

.211

.631**

.287

.411*

.355*

.217

.152

1

.401*

.511**

.188

.827**

.222

.339

.541**

.183

.308

1

.651**

.231

.481**

.123

.166

-.059

.212

.031

1

.243

.345

-.087

.170

.350

.319

.104

1

.375*

.193

.305

-.213

.040

.058

1

.417*

.376*

.239

.299

.122

1

.376*

.239

.299

.224

1

.246

-.078

.333

1

-.099

.310

1

-.319

* p < .05 (2-tailed)
** p < .01 (2-tailed)

1
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Observational Analyses
Sex. Initially, Mann-Whitney U-tests were performed to compare potential differences in
male and female participants’ CD-RISC total Scores and Global Health Status/QoL scale scores.
No statistically significant difference was observed for either comparison. Sex was then graphed
against the CD-RISC total scores and against the Global Health Status/QoL scale scores (Figure
2 and Figure 3, respectively). Although females only represented 25.8% of the sample, Figures 2
and 3 cautiously suggest that their CD-RISC total scores and Global Health Status/QoL scale
scores tended to be higher.

Figure 2. Comparison of CD-RISC total scores and sex.
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Figure 3. Comparison of Global Health Status/QoL and sex.

Age. Correlational analysis of both CD-RISC total scores and Global Health Status/QoL
scale scores with age did not reveal a statistically significant relationship. However, when raw
data for the CD-RISC are graphed against participant age, a slight negative slope can be
observed. When Global Health Status/QoL scale scores are graphed against age, a negative slope
also exists. Figures 4 and 5 display comparisons of CD-RISC total scores and Global Health
Status/QoL scale scores with age, respectively.
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Figure 4. Comparison of CD-RISC total scores and participant age.

Figure 5. Comparison of Global Health Status/QoL scale scores and participant age.
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Site of cancer. Figure 6 displays the site of cancer graphed against CD-RISC total scores.
Based on visual analysis, no clear trend exists between these factors. The site of cancer is
graphed against the scale scores for Global Health Status/QoL in Figure 7. Similarly, no clear
visual trend is observable between cancer site and Global Health Status/QoL scale scores.

Figure 6. Comparison of CD-RISC total scores and site of cancer.
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Figure 7. Comparison of Global Health Status/QoL scale scores and site of cancer.

Clinical stage of cancer. Figure 8 displays the clinical stage of cancer graphed against
the CD-RISC total scores. No visible trend is present. Figure 9 displays the clinical stage of
cancer graphed against the scale scores for Global Health Status/QoL and, again, no visual trend
is observable.
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Figure 8. Comparison of CD-RISC total scores and clinical stage of cancer.

Figure 9. Comparison of Global Health Status/QoL scale scores and clinical stage of cancer.
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Treatment modality. Figure 10 displays treatment modality graphed against participant
total scores for the CD-RISCs. Based on visual analysis, two natural groups are apparent: those
who received surgery alone and those who received surgery and radiation therapy. Visual
comparison of these groups suggests similar levels of resilience (see Figure 10). Treatment
modality was also graphed against the scale scores for Global Health Status/QoL (see Figure 11).
Once again, two treatment modality groups are present and, similarly, the group of individuals
who received surgery alone and the group that received surgery and radiation therapy display
very similar levels of perceived QoL.

Figure 10. Comparison of CD-RISC total scores and treatment modality.
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Figure 11. Comparison of Global Health Status/QoL scale scores and treatment modality.

Time since diagnosis. When the CD-RISC total scores were graphed against time since
diagnosis (in months), a positive slope can be observed (Figure 12). When Global Health
Status/QoL scale scores are graphed against time since diagnosis, a slight decline in Global
Health Status/QoL scale scores with increasing time is suggested (Figure 13).
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Figure 12. Comparison of CD-RISC total score and months since diagnosis.

Figure 13. Comparison of Global Health Status/QoL scale scores and months since diagnosis.
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Time since treatment completion. A positive slope can be observed when CD-RISC
total scores are graphed against time since treatment completion (in months) (Figure 14). When
Global Health Status/QoL scale scores are graphed against time since treatment completion, the
data suggest a slight decline in Global Health Status/QoL scale scores with increasing time posttreatment (Figure 15).

Figure 14. Comparison of CD-RISC total scores and months since treatment completion.
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Figure 15. Comparison of Global Health Status/QoL scale scores and months since treatment
completion.
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CHAPTER 4
Discussion
This study was designed to identify the presence of resilience in individuals who had
completed treatment for HNCa and to explore the potential relationship between resilience and
QoL. Thus, the primary aim of the study centred on the identification of resilience in HNCa
survivors. This study also sought to identify the potential role of resilience in buffering the
adverse impact of HNCa and its treatment on QoL. Accordingly, the specific objectives of the
study were to:
1. Identify the presence of resilience in a sample of individuals who had completed curative
treatment for HNCa and,
2. Determine if a relationship exists between individuals’ resilience and QoL in the context
of their survivorship experience with HNCa.
In the pursuit of fulfilling these study objectives, data pertaining to resilience and QoL
were collected using the Connor-Davidson Resilience Scale (CD-RISC), European Organisation
for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30),
and European Organisation for the Research and Treatment of Cancer Head and Neck Cancer
Module (EORTC QLQ-H&N35). The two EORTC questionnaires also provided data on areas of
functioning and groupings of symptoms that are pertinent to HNCa survivors and their valuation
of QoL. In the sections to follow, a comprehensive discussion of the findings from the CD-RISC,
EORTC QLQ-C30, and EORTC QLQ-H&N35 will be presented. This will be followed by a
discussion of relationships identified between the measures. Observational analyses of
demographic data (e.g., sex, age, site of cancer, clinical stage of cancer, treatment modality, time
since diagnosis, and time since treatment completion) and resilience and global QoL will
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subsequently be discussed. Finally, limitations of the present study, clinical implications of the
findings, and directions for future research will be offered.
CD-RISC
In order to quantify the presence of resilience, the CD-RISC was developed (Connor &
Davidson, 2003). The CD-RISC consists of 25 items that are summed to generate a total score
that represents the quantified level of resilience, where higher scores reflect greater levels of
resilience (Davidson & Connor, 2016). Since no clinically significant score has been established
by the authors of the CD-RISC, a total score of 50 was arbitrarily selected to demarcate those
participants with a lower level of resilience from those with a higher level. More specifically,
participants who scored below 50 were identified as minimally resilient, while participants who
scored 50 and above were identified to be more highly resilient. Descriptive statistics for the CDRISC indicated that on average, the vast majority of participants (96.8%) scored above the
arbitrary threshold score of 50; thus, the overall data obtained tended to reflect higher levels of
resilience (mean = 79.3, SD=17.7). Thus, resilience was indeed identified in the present study’s
sample of HNCa survivors.
Interestingly, among the 25 items on the CD-RISC, item 25 was agreed with most, since
on average, participants considered taking pride in one’s achievements to be true nearly all the
time (mean = 3.52). Item 3 was the least agreed with item; participants tended to consider relying
on fate or God to help with problem solving rarely to be true (mean = 2.23). Nonetheless,
participants’ level of agreement with item 3 also was quite varied (SD = 1.69, range = 4),
indicating that the presence or absence of some form of spirituality may have an individualized
influence on one’s approach to solving problems. Identification of domains that may contribute
to resilience, as indicated by resilient individuals’ responses to items on the CD-RISC, may serve
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to inform potential targets for interventions that aim to foster resilience (e.g., encouraging
recognition of past successes or achievements) in unique populations, such as HNCa survivors.
The data on overall resilience in HNCa survivors suggest that those who have completed
treatment have resilience scores that are similar to normative comparative samples for the CDRISC that were developed with a general population sample (Connor & Davidson, 2003). This
comparative sample provided a mean total score of 80.4 on the CD-RISC (SD=12.8, n=577)
(Connor & Davidson, 2003). Interestingly, the similarity between the mean total scores of
resilience in the sample of the general population and the present sample of HNCa survivors
suggests that HNCa does not uniquely influence resilience, but just acts as an event of sufficient
adversity that triggers resilience. Therefore, it may be suggested that the disablement experience
of HNCa does not distinctively modify the level of resilience of those individuals who have
completed treatment. In essence, despite different encounters of adversity throughout the lifespan
(i.e., encountering the disablement experience of HNCa), the interactive process of protective
and risk factors at intrapersonal and environmental levels still yields a comparative level of
resilience in those who have experienced HNCa compared to those who have not.
Consideration of previously reported CD-RISC mean total scores from studies carried out
in patient groups with a variety of cancers and at various time points throughout the clinical
pathway is also relevant. The mean total score of resilience in the present sample of individuals
who had completed treatment for HNCa is somewhat elevated from the levels of resilience
reported in previous studies. For instance, in a study by Dubey, De Maria, Hoeppli, Betticher,
and Eicher (2015) the CD-RISC was administered to a sample of male and female cancer
patients in Switzerland (n=68, mean age=63.2). The participants in their study were in the early
stages of treatment (4-15 weeks since diagnosis) for a variety of cancers, in which HNCa (n=5)
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was included as a subgroup. The mean total score was reported to be 74.4 (SD=12.6) among the
entire sample that included the various tumour sites and 68.2 (SD=14.8) for the HNCa subgroup.
Additionally, in a randomized pilot clinical trial conducted by Loprinzi, Prasad, Schroeder, and
Sood (2011) the effect of a stress management and resilience training program was assessed in a
sample of breast cancer survivors (n=20, mean age=61) in the United States. Prior to the
commencement of the training program, baseline mean total scores for the CD-RISC were
reported to be 73.6 (SD=10.1) and 78.2 (SD=12.6) for the individuals assigned to the active arm
(n=12) and control arm (n=8), respectively. It can be noted that an increase in CD-RISC total
scores was observed following the completion of their training program. However, given the
objective of the present study, comparison is only warranted with the baseline levels of resilience
reported in the study by Loprinzi et al. (2011).
Upon comparison between the mean resilience score found in the present study and the
means reported in previous studies, it is evident that variation exists in the level of resilience in
individuals who have been diagnosed with cancer. However, upon careful consideration, perhaps
the varied time points at which resilience was measured and quantified in the previous studies
limits the ability to fully generalize the previous findings to those of the present study. More
specifically, Dubey et al. (2015) measured participants’ resilience levels in the early stages of
their treatment; in contrast, the present study was interested in the presence of resilience after
participants had completed active treatment. Although the participants in the study by Loprinzi et
al. (2011) were diagnosed with breast cancer, both their study and the present study utilized the
CD-RISC to measure resilience after treatment completion. Thus, the similarity in the timing of
the measurement of resilience may render the mean resilience scores more comparable.
Therefore, when the study designs are taken into account (i.e., comparable time reference and
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“n” value), the mean resilience score found in the present study (79.3) is consistent with the level
of resilience reported by Loprinzi et al. (2011).
Given the variability of CD-RISC scores among those involved in the present study
(range = 10-100, SD=17.7), it is apparent that resilience is highly individualized. That is, each
individual will have encountered different life events, including different developmental
experiences during childhood and different protective and risk factors during adulthood.
Ultimately, these different life experiences may influence the position of the proverbial fulcrum
in the resilience balance scale. Although the current inclusion and exclusion criteria were
stipulated in an attempt to limit extraneous diversity within the sample, it was impossible to
screen out all individual differences that may influence resilience (e.g., past experience coping,
and factors of child development that contribute to emotional regulation and executive
functioning). The effect of individual differences on resilience, as measured with the CD-RISC,
could have been exaggerated due to the small sample size and the fact that convenience sampling
was employed. However, despite the potential influence of individual differences on resilience,
the mean resilience score found in the present study (79.3) is still consistent with the resilience
score found in the aforementioned comparable study (78.2) (Loprinzi et al., 2011).
EORTC QLQ-C30
Due to the potential biopsychosocial challenges that may result secondary to HNCa and
its treatment, a central objective of the present study was to investigate perceived QoL, both
globally and in relation to various domains of functioning and symptoms recognized to be
potentially disabling to those with cancer. The 30 items of the QLQ-C30 address common
concerns of cancer patients. Following linear transformation of the raw scores, the data from
each item are categorized into Functioning Scales, Symptom Scales, Single Item Measures, and a
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Global Health Status/QoL Scale. The resultant QLQ-C30 data may then be used to summarize
individuals’ multifaceted disablement experience secondary to their cancer.
First, participants’ responses to the 30 items of the QLQ-C30 suggest that the majority
rarely, if at all, experienced the challenges and concerns addressed by the questionnaire.
However, participants reported the greatest level of challenge with question 11, which asks
“Have you had trouble sleeping?”. This was consistent with the responses to the Symptom Scales
and Single Item Measures; the Insomnia Single Item Measure was found to represent the
participants’ highest reported level of symptomology or challenge. The findings of the present
study are in line with previous studies conducted by Duffy et al. (2008) and Shuman et al. (2010)
who found that sleeping problems are a common issue for HNCa survivors. Furthermore, Irwin
(2013) reported that insomnia can continue into extended survivorship, a finding that is also in
line with those of the present study. Interestingly, Irwin (2013), Shuman et al. (2010), and Duffy
et al. (2008) posit that insomnia experienced by HNCa survivors may be attributable to
psychological sequelae associated with the disease and its treatment, such as depression, distress,
and anxiety. Since these psychological challenges are characteristic of those experienced by
HNCa survivors (Bornbaum et al., 2012; Cohen et al., 2015; Howren et al., 2012), the finding
that participants experienced a high degree of challenge with sleeping problems is
understandable.
Accordingly, among the Functional Scales, participants reported the lowest level of
functioning in the emotional domain. The Emotional Functioning Scale reflects items that ask if
the individual has felt tense, has worried, been irritable, and/or felt depressed (questions 21-24).
As such, it is notable that the diagnosis of HNCa is associated with a higher prevalence of
depression when compared to the rates of depression among other oncological populations

88

(Howren et al., 2012). In addition to depression, substantial disruption to psychological
functioning is also evidenced by a high representation of worry and anxiety in HNCa
survivorship populations (Cohen et al., 2015; Stanton et al., 2015). Interestingly, among the four
items that factor into the QLQ-C30 Emotional Functioning Scale, questions 22 (“Did you
worry?”) and 24 (“Did you feel depressed?”) indicate that participants felt worried and depressed
to a greater degree than they experienced the concerns alluded to by questions 21 (“Did you feel
tense?”) and 23 (“Did you feel irritable?”). As such, the findings pertaining to depression,
anxiety and emotional functioning are consistent with the published literature (Cohen et al.,
2015; Howren et al., 2012; Stanton et al., 2015).
In addition to the low scores reported for the Emotional Functioning Scale, participants
from the present study reported an equally low average level of functioning in the Social
Functioning Scale. Correspondingly, an individual’s inhibited ability to communicate and
capacity to engage socially is commonly linked with psychological dysfunction (e.g., depression)
(Howren et al., 2012), which was also reported by the participants of the present study. Thus, the
interdependent and multidimensional nature of the functional deficits experienced by HNCa
survivors is highlighted. The diminished social functioning reported by participants is of
particular concern since it has been well established that finding support through social
interaction is correlated with positive adjustment to one’s experience of disease (McDonough et
al., 1996). Analogously, it follows that social support and functioning is also of relevance to
resilience which is congruent with the findings of the present study.
The concurrent identification of elevated dysfunction in the domains of emotional and
social functioning also speaks to the reality of the notion that the psychosocial impact of
survivorship is commonly more challenging than the direct effects of physical treatment sequelae
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(Wolff, 2007). Furthermore, the fact that the participants ranged from 1 to 59 months post
treatment and, thus, were in the extended phase of survivorship, is in line with the notion that
extended survivorship is commonly associated with psychosocial burden (Stanton et al., 2015).
Thus, after the objective biological aspects of the disease have been resolved, suffering related to
the subjective dimensions of disablement remains and may be difficult to overcome (Ueda &
Okawa, 2003). Since the subjective psychosocial consequences of the disease may be more
challenging to surmount than the physical aspects, diminished coping and adjustment may occur
secondary to unresolved suffering in the psychosocial domain of disablement (McDonough et al.,
1996).
In relation to the psychosocial dysfunction reported by the participants, it is interesting to
note that 96.8% of the sample of HNCa survivors were found to be highly resilient. Given the
concurrent presence of both resilience and psychosocial dysfunction, this finding supports the
notion that highly resilient individuals are not immune to negative emotions or risk factors
(Markovitz et al., 2015; Molina et al., 2012). As such, the results of the present study mirror the
notion that resilience is a process whereby protective factors may act to buffer risk factors, but
they do not eliminate them (Werner, 2000). Instead, it appears that resilience may allow the
individual to deal more effectively with stressors that may cause emotional disturbance. This
observation may be supported by the finding that although participants reported the lowest levels
of functioning in emotional and social domains, the quantified level of dysfunction was not to an
extreme (i.e., the scale scores for emotional and social functioning were 86.02; a score of 100
denotes no perceived functional challenge). Thus, since no causal relationship can be concluded
from the present study, delineating the nature of the interaction between resilience and HNCa
survivors’ experience of dysfunction and symptomology warrants further study.
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Furthermore, in addition to reporting minimal levels of dysfunction and symptomology,
the current participants also reported nearly optimal levels of QoL. In light of the findings of the
CD-RISC, the role of the quantifiably high level of resilience in ameliorating the participants’
perceptions of their experience of dysfunction and symptomology, and, in turn, buffering the
influence of the potential challenges of HNCa and its treatment on perceived QoL can be called
to question. However, it is important to note the relationship that exists between resilience and
QoL may simply be characterized as coexistent. To provide additional information that may
serve to contextualize the relationship between resilience and QoL in HNCa survivors
specifically, the EORTC QLQ-H&N35 was employed.
EORTC QLQ-H&H35
To supplement the QLQ-C30 core questionnaire, the QLQ-H&N35 was also utilized to
gather information pertaining to areas of concern specifically for individuals diagnosed with
HNCa. The items of the QLQ-H&N35 are intended to cover the HNCa disablement experience
by addressing issues pertaining to disease and treatment related symptoms and side effects, as
well as issues associated with social function and sexuality. By extension, the items on the QLQH&N35 should cover symptomology that are pertinent to participants of the present study.
However, the majority of participants indicated that they did not experience the symptoms
addressed by this HNCa specific module. The exception to this general trend can be observed
through the markedly higher mean score of question 11, which asks “Have you had a dry
mouth?”. Accordingly, the most commonly reported challenge associated specifically with
HNCa and its treatment as quantified by Symptom Scales and Single Item measures of the QLQH&N35, was the Dry Mouth Single Item Measure. In line with the findings of the present study,
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the perception of dryness in the oral cavity, or xerostomia, commonly occurs secondary to
radiation and/or chemotherapy (Marur et al., 2016).
Xerostomia could be considered an overtly medical and primarily physiological health
condition; however, from a biopsychosocial perspective, xerostomia may also heavily influence
social functioning. For instance, since the sensation of a dry mouth commonly augments the
burden of dysphagia (Pauloski, 2008), xerostomia is a physical consequence of HNCa treatment
that may limit one’s ability to engage in shared meal times in social settings which may then
result in social isolation (Pateman et al., 2015; Threats, 2007). Thus, results of the QLQ-H&N35
may be viewed as complimentary to the findings of the QLQ-C30 that found that some
participants experienced elevated levels of dysfunction in the social domain. Furthermore, given
the concurrent identification of participants’ experience of physical symptomology (dry mouth)
and social dysfunction, the interrelated and multifaceted nature of the functional deficits
experienced by HNCa survivors is apparent in the results of the present study. Ultimately, this
finding suggests that it is important to approach the concerns of HNCa survivors through a
biopsychosocial lens, as to not be blinded to the potential influence of one concern on a wide
array of additional domains of functioning. Thus, consideration of relationships that may exist
among the multitude of challenges faced by HNCa survivors and resilience and QoL warrants
further discussion.
Correlational Analyses
Resilience and QoL. Based on findings from correlational analysis it was determined
that a strong and statistically significant positive relationship exists between resilience scores and
global QoL scores. As such, this positive relationship suggests that as individuals’ resilience
increases, their perceived QoL also increases, whereby the level of resilience is indicated by
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higher total scores on the CD-RISC and perceived QoL is illustrated by higher scale scores on
the Global Health Status/QoL Scale on the QLQ-C30.
Conceptually, the positive relationship found between resilience and QoL is not a
surprising finding. Resilience is understood to be the process of positive adaptation in the pursuit
of homeostatic functioning in physical, psychological, and social domains in the context of
adverse circumstances (Gillespie et al., 2007; Pieters, 2016). Somewhat congruently, QoL
denotes an individual’s perception of his or her physical, psychological, and social functioning
and well-being (WHO, 1997). If positive adaptation occurs within the domains of functioning,
perceived changes to QoL could be expected. It follows conceptually that resilience, at a
minimum, may directly influence the psychosocial aspect of QoL, and may mediate the
relationship between the HNCa disablement experience and survivors’ QoL (Tian & Hong,
2014; Wu et al., 2015). This suggests that resilience may play a protective role in buffering the
adverse influence of the HNCa disablement experience on QoL. It is important to note, however,
that the positive relationship identified between resilience and QoL does not suggest causal
interaction, but rather, that the two constructs vary together.
While numerous studies have explored QoL in HNCa survivors, limited data exist on the
presence of resilience in this unique population. Consequently, little evidence has served to
elucidate the relationship between resilience and QoL in the context of an individual’s
experience with HNCa. That being said, the findings of the present study are consistent with
those of Tian and Hong (2014). In their study, Tian and Hong (2014) reported that a relationship
existed between resilience and QoL in individuals diagnosed with digestive cancer; however,
they stated that the nature of this relationship was not fully understood. Additional research will
be required to further delineate this relationship. In addition to the relationship found between
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resilience and QoL in the present study, a number of other relationships were identified between
resilience, QoL, and various domains of functioning and symptomology. These relationships will
be discussed in the sections to follow.
Resilience and social functioning. Strong, statistically significant relationships were
found between resilience and scales that measured various aspects of social functioning, namely,
the Social Functioning Scale (p<0.01) from the QLQ-C30, and the Social Contact (p<0.01) and
Social Eating Symptom Scales (p<0.05) from the QLQ-H&N35. In light of the substantial
challenges a HNCa survivor may face in the social domain of functioning, the identification of a
relationship between social functioning and resilience becomes particularly intriguing.
The correlation between resilience and the Social Functioning Scale was characterized as
a positive relationship, while the correlations between resilience and the Social Contact and the
Social Eating Symptom Scales were found to be inverse relationships. The conflicting positive
and negative relationships become logical upon consideration of the difference in interpretation
of the Functioning Scale Scores on the QLQ-C30 and the Symptom Scale Scores on the QLQH&N35; a high score on a functioning scale denotes a better level of functioning, whereas a high
score on a Symptom Scales indicates a greater perceived level of challenge or problem in the
scale’s content area. Thus, the statistically significant positive relationship found between
resilience and social functioning suggests that as individuals’ levels of resilience increase, their
social functioning also improves. Accordingly, the statistically significant inverse relationship
found between resilience and challenges with social contact and social eating implies that as
HNCa survivors’ resilience decreases, they experience greater challenge in terms of their
experience with social contact and social eating.
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Upon review of the literature, it is apparent that the connection found between resilience
and social functioning in the present study is consistent with past research. Connor and Davidson
(2003) include “engaging the support of others” (p. 77), as a salient characteristic of resilience.
The ability to seek social support from others is intrinsically integral to an individual’s healthy
social functioning. Thus, it follows logically that resilience would be positively correlated to
social functioning and negatively correlated to a high degree of trouble with social contact.
Additionally, Dubey et al. (2015) cite strong social support systems that may include family
members, significant others, and peers as central protective factors that are fundamental to
resilience. Given previous findings in published literature and the findings of the present study, it
appears that individuals’ capacity for strong social functioning interacts with their resilience;
however, the causality of this interaction remains unknown and, in actual fact, the two factors
may simply vary together.
While causal relationships cannot be concluded from the results of the present study, it is
difficult to ignore the potential link to the foundational development of resilience that occurs
during childhood. More directly, as part of the foundation that is laid during childhood, the single
most common variable that predicts the development of resilience is the presence of a secure and
supportive relationship (National Scientific Council on the Developing Child, 2015). This
finding suggests the inverse relationship between resilience and challenges with social
functioning exist throughout the lifespan. For instance, starting in the formative years of
childhood, the higher the level of social challenge experienced, the lower the level of resilience.
Thus, it may be speculated that the identified relationship may illustrate that social dysfunction
acts to threaten the development and/or expression of resilience, however, it may also illustrate
that resilience acts to buffer the experience of social dysfunction. It is important to note that a
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third explanation may exist; the relationship may simply illustrate that resilience and social
functioning vary together. Ultimately, the precipitating factor in this relationship cannot be
determined from the results of the present study. However, it is apparent that a relationship exists
between strong and healthy social functioning and one’s ability to be resilient.
It is also interesting to note an additional area of concern identified by the QLQ-H&N35
that is observationally connected to HNCa survivors’ capacity to function socially and, thus, may
influence their resilience. A moderately significant negative correlation was identified between
the Speech Symptom Scale and both resilience and QoL. Given the central role of verbal
communication in social interaction, speech and voice deficits are widely accepted to impair
social functioning (Eadie et al., 2015). The conspicuous nature of speech and voice deficits that
are associated with HNCa and its treatment, has been well documented to precipitate impaired
social functioning and the potential for social isolation (Doyle, 2005; Howren et al., 2012;
Semple et al., 2004). Furthermore, the resultant social dysfunction and the potential for
perceived stigma of not conforming to social norms, interact innately with perceived QoL
(Doyle, 2005; Howren et al., 2012; Semple et al., 2004). Nevertheless, social dysfunction is just
one of the many issues that may influence the QoL of a HNCa survivor. Thus, consideration of
the relationships found between QoL and functional domains is of relevance.
QoL and functional domains. By definition, QoL is a multidimensional construct. The
HNCa survivorship experience has the potential to influence the biopsychosocial dimensions that
may be central to a survivor’s valuation of his or her QoL. This sentiment is mirrored by the
findings of the present study which suggest that each of the five domains of functioning covered
in the QLQ-C30 had strong-to-moderate positive relationships with global QoL. In addition to
the multidimensionality of QoL, the interdependent nature of the domains that may contribute to
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QoL was also observed. That is, the positive significant relationships that were also found
between all five domains of functioning alludes to the reciprocal nature of their mutual
connections. Among the five domains, Emotional Functioning was found to have the strongest
correlation to global QoL. This finding is complementary to the previously stated findings of the
present study that indicated that emotional functioning is a salient issue experienced by HNCa
survivors. The correlation found between QoL and emotional functioning is also consistent with
previous studies that have reported that emotional functioning has a well-documented
relationship with survivors’ valuation of QoL (Carlson & Bultz, 2004).
In light of the correlations found between resilience and social functioning, it is
interesting to note that the Social Functioning Scale had the second highest correlation with QoL.
The Social Contact Symptom Scale and the Social Eating Symptom Scale on the QLQ-H&N35
were also found to be significantly correlated with QoL. Similar to the relationships identified
with resilience, a positive correlation was revealed between the Social Functioning Scale and
QoL, while negative correlations were found between the two Symptom Scales and QoL.
Collectively, these data suggest that as social functioning increases and challenges pertaining to
social eating and contact decrease, a HNCa survivor’s QoL increases.
Resilience, QoL, and symptomology. The strongest correlation found among resilience
and the Symptom Scales and the Single Item Measures of the QLQ-C30 was an inverse
relationship between resilience and dyspnea. While it is not readily apparent how dyspnea is
related to resilience, the negative relationship found between this physical sequela of HNCa and
resilience cannot be overlooked. While the causal nature of this relationship is unknown, the
experience of dyspnea may represent a risk factor that acts to shift the equilibrium of the
survivor’s proverbial resilience balance scale towards negative outcomes. As such, the findings
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of the present study indicate that as one’s challenge with dyspnea increases, resilience decreases.
The interaction between dyspnea and resilience may also have something to do with the other
significant inverse relationships identified between dyspnea and physical, social, and emotional
functioning. Since it was found that as dyspnea increases, physical, social, and emotional
functioning decrease, the cumulative impact of the experience of difficulty breathing on
survivors’ functioning may ultimately shed light on the interaction between dyspnea and
resilience.
Additionally, the QLQ-C30 symptom scale that represents an individual’s experience of
pain was found to have strong-to-moderately significant inverse relationships with both
resilience and QoL. While it is not surprising that as a HNCa survivor’s experience of pain
increases, his or her resilience and QoL may decrease, what is interesting is that pain was found
to correlate with many other areas of functioning that may not be initially obvious. While pain is
correlated with resilience and QoL, significant negative correlations were also found between
pain and domains of physical, role, emotional, and social functioning, in addition to significant
positive correlations between pain and the experience of fatigue, nausea, dyspnea, insomnia, and
diarrhea. Once again, the highly interrelated and multidimensional nature of the myriad
challenges potentially experienced by HNCa survivors may be observed through the
relationships found in the present study. Thus, not only is pain known to impact at least half of
individuals with HNCa (Howren et al., 2012), the experience of pain extends its extremely broad
influence to envelop the multitude of functional domains included on the QLQ-C30. Therefore,
the importance of monitoring pain in HNCa patients cannot be overstated (Howren et al., 2012).
While the identification of a significant negative correlation between fatigue and QoL is
consistent with previous studies (Carlson & Bultz, 2004; Romito, Montanaro, Corvasce, Di
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Bisceglie, & Mattioli, 2008; Scott, 2015; Visser & Smets, 1998), it is of particular interest to
note that fatigue was also found to have significant negative correlations with all five
Functioning Scales on the QLQ-C30. Thus, a HNCa survivor’s experience of fatigue may not
only be associated with decreased QoL, but also decreased functioning in multiple domains.
Similarly, insomnia was also found to have a significant negative relationship with QoL, in
addition to significant negative relationships with physical, role, and emotional functioning, and
positive relationships with fatigue and pain. Therefore, it may be suggested that when a HNCa
survivor presents with a single concern (e.g., pain, fatigue or insomnia), there may be many
underlying issues (e.g., social, emotional, and/or role dysfunction) that may not be directly
apparent. Attending to a survivor’s holistic experience of disablement may allow for the
identification of individuals who are not forthcoming with psychosocial issues, and yet, are
struggling to cope (Carlson & Bultz, 2004). Understanding the synergistic associations between
common morbidities faced by HNCa survivors has important implications for short and longterm recovery and cancer rehabilitation. While future research is required to fully elucidate
groupings of interrelated symptoms, the identification of biopsychosocial symptom clusters may
serve to inform rehabilitation efforts. In turn, these efforts may work to aid survivors’ resumption
of homeostatic levels of functioning and combat the risk of declines in QoL that occur secondary
to the biopsychosocial disablement experience of HNCa.
Symptomology on the EORTC QLQ-H&N35. The QLQ-H&N35 module assesses
areas of concern that are specifically tailored to individuals who have been diagnosed with
HNCa. As such, relations that may exist with resilience, global QoL, and areas of concern
captured by the QLQ-H&N35 that were not captured by the QLQ-C30, which is designed for use
in general oncological populations irrespective of disease site, were explored. For instance, the
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strong-to-moderate negative correlation between the Teeth Single Item Measure and both
resilience and QoL would not have been identified without the use of the QLQ-H&N35. The
same can be said for the significant and strong negative relationship found between the
Nutritional Supplements Single Item Measure and QoL. Finally, the same applies to the
moderately significant negative relationships found between the single item measures pertaining
to “feeling ill” and use of pain killers and QoL. The QLQ-H&N35 ultimately identified issues
unique to HNCa that had additional relationships with survivors’ resilience and QoL. However,
in addition to the myriad challenges identified by both the QLQ-C30 and the QLQ-H&N35,
demographic characteristics also have potential connections to a HNCa survivor’s resilience and
QoL. Thus, consideration of demographic characteristics warrants discussion.
Observational Analyses of Demographic Characteristics
As anticipated, given limitations associated with the small sample size (N=31) and the
fact that it was a sample of convenience, no statistically significant relationships were observed
between resilience and the demographic characteristics of the HNCa survivors that participated.
However, observational analyses of the demographic variables that include participant sex, age,
site of cancer, clinical stage of cancer, treatment modality, and elapsed time since diagnosis and
treatment completion deserves some comment.
Sex. First and foremost, it must be noted that females were substantially underrepresented
in the present sample; thus, findings pertaining to resilience, QoL and sex are speculative.
Although it cannot be verified statistically, resilience tended to be higher in females than males
in the present sample. In light of the significant relationship found between resilience and social
functioning, it could be suggested that female participants tended to be more resilient since
females tend to seek and receive a higher degree of social support than males which may

100

augment positive adjustment to disease (Bekes, Beaulieu-Prevost, Guay, Belleville, & Marchand,
2016). In essence, since strong social functioning is associated with resilience, women may
benefit from their inclination towards social engagement in coping with challenges.
Conflicting data exist in the literature pertaining to the effects of gender on resilience. For
instance, while Pudrovska (2010) did not investigate resilience, it was found that men were more
vulnerable to the adverse psychosocial consequences of cancer. However, since a low level of
resilience is likely indicative of a high level of vulnerability to psychosocial dysfunction
(Markovitz et al., 2015), if resilience had been assessed by Pudrovska (2010), a lower level of
resilience may also have been found in males. However, Bonanno, Galea, Bucciarelli, and
Vlahov (2007), as well as Cohen, Bazilianski, and Beny (2013) reported that resilience tends to
be lower in females compared to males. Neither Bonanno et al. (2007) or Cohen et al. (2013)
offered insights into the reasons why the male sex was correlated with increased resilience.
Clearly, the moderating effects of gender on resilience warrants future research.
Age. The present study found negligible changes in the level of resilience in HNCa
survivors with increasing participant age. This finding suggests that one’s capacity for resilience
does not depend on age. However, published research literature suggests multiple conflicting
explanations for the impact of age on resilience. For instance, the accumulation of adversities in
addition to the effects of physical and cognitive decline and loss of personal resources that
occurs with increasing age, may in turn, weaken resilience (Cohen et al., 2013). More
optimistically, resilience may be strengthened with increasing age as a result of gained
experience and enhancement of efficient coping strategies that accompanies increased encounters
with challenging situations (Brandtstadter, 1999).
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Relative to individuals with cancer, Cohen et al. (2013) found that resilience increased
with age in their sample of individuals with colorectal cancer. However, in light of the multiple
explanations of the effects of age on resilience that exist in the literature, additional research is
needed to further investigate this potential relationship in those with HNCa. Additionally,
contrary to the general consensus of QoL literature which suggests that older individuals exhibit
better QoL following treatment for HNCa (Pandey, Devi, Ramdas, Krishnan, & Kumar, 2009),
the present study found that QoL tended to be lower in older HNCa survivors. This conflicting
result may simply be explained by the small sample of convenience utilized in the present study.
Site of HNCa, clinical stage, and treatment modality. The sample size of the present
study was small, which meant that when it was divided into subcategories within HNCa site,
stage, and treatment modality, the subgroups were even smaller. As such, no clearly discernable
trends were apparent through observational analyses. The apparent lack of marked difference
between the subgroups within the site, stage, and treatment modality data, would suggest that
these three demographic variables have no impact on resilience and QoL. Although no clear
trends were identified, it is conceivable that certain outcomes associated with the various
categorical subgroups (e.g., later staged cancer, total laryngeal deletion) within each of these
three variables may pose different challenges that may oppose an individual’s ability to be
resilient or threaten QoL. While limited data on the impact of HNCa site and treatment modality
on resilience exists, the present findings pertaining to stage of cancer was consistent with a study
of resilience in individuals with colorectal cancer (Cohen et al., 2013). Although site and
treatment modality were not considered, no association was found between resilience and stage
of cancer in individuals with colorectal cancer (Cohen et al., 2013).
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Time since diagnosis and completion of treatment. Graphical representations of
resilience and time since diagnosis and treatment completion revealed a slight increase in
resilience with increasing time. However, substantial variation was observed. Additionally,
graphical representations of QoL and time since diagnosis and treatment completion also display
a substantial amount of variability. Although strictly speculative, given this variability in
resilience and QoL with time since diagnosis and treatment, it may be suggested that the
idiosyncratic interaction of protective and risk factors augment the influence of passing time to
further impact one’s level of resilience and, hypothetically, the ameliorating influence of
resilience on a HNCa survivor’s perceived QoL. Although data on the influence of time since
diagnosis and treatment of cancer is limited in the resilience literature, Sharpley, Wooten,
Bitsika, and Christie (2013) found substantial variability in resilience over time in individuals
diagnosed with prostate cancer. Their findings, as well as those of the present study suggest that
resilience may not follow a clear-cut pattern, but instead resembles a fluid trajectory that is
highly individualized and may ebb and flow as time passes.
Since the participants’ demographic characteristics did not serve to clarify the high level
of resilience identified in this sample, the previously stated relationships between various aspects
of functioning and symptomology associated with the disablement experience of HNCa may
provide a more perceptive understanding of the factors related to the presence of resilience in
survivors of HNCa.
Limitations of the Current Study
Limitations of the present study must be acknowledged. To begin, several
methodological limitations existed relative to data acquisition. Data were collected solely from
one tertiary care institution and, thus, the generalizability of the present results to individuals

103

diagnosed and treated in different institutions may be limited. Furthermore, because this was a
sample of convenience, assumptions cannot be made about the resilience and QoL of individuals
who chose not to participate. As is the case with most studies involving clinical populations, the
current findings are based on a small sample size (N=31). Thus, causal conclusions relative to
the present findings on resilience and QoL in HNCa survivors cannot be drawn definitively and
external validity concerns must be acknowledged.
More specifically, concerns pertaining to external validity are directed to the
representativeness of the present sample of HNCa survivors. The present sample may not
provide a fully representative indication of the whole population of individuals who have been
diagnosed with and treated for HNCa. For instance, while the sample depicted in the current
study only included two participants diagnosed with thyroid cancer, The Canadian Cancer
Society (2017) reported that thyroid cancer has the highest incidence among all HNCa diagnoses.
Further, the high representation of oral cavity cancer and laryngeal cancer in the present sample
reflect the fact that these two cancers have the second and third highest incidences among all
HNCa sites (Canadian Cancer Society, 2017). However, some common groupings within the
larger HNCa category were substantially underrepresented in the present sample since there was
only one participant diagnosed with nasopharyngeal cancer and none diagnosed with
oropharyngeal or hypopharyngeal cancers. Thus, although the present study found that HNCa
survivors tended to be highly resilient, due to external validity concerns, generalizability of the
present data to others with HNCa should be done with caution.
Due to the exploratory nature of the present study, inclusion criteria allowed for
substantial demographic variability (i.e., sex, age, site and stage of cancer, treatment modality,
and time since diagnosis and treatment). As a result, there was considerable skew in the results
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which further limits potential conclusions related to mediating or moderating factors that may
influence measures of resilience or QoL. Finally, data were collected at a single point in time.
Therefore, the results of these data do not portray the potentially fluid nature of resilience and
perceived QoL throughout the HNCa survivorship experience. However, despite the noted
limitations, the present data may provide insights into variables of interest that can be explored in
the future.
Clinical Implications
From a clinical perspective, several implications arise from the findings of the present
study that not only suggest that remarkable resilience is exhibited by HNCa survivors, but also
that a significant relationship exists between their resilience and QoL. A range of clinically
meaningful implications may exist for the construct of resilience that pertain to the minimization
of the impact of HNCa and the maximization of QoL. Nonetheless, the presence of resilience
must first be identified. As such, screening for resilience may present as an opportunity for early
identification of individuals with lower levels of resilience and, thus, potentially higher
vulnerability for the development of psychosocial challenges (Markovitz et al., 2015). Following
identification of those that are more vulnerable to the impact of psychosocial challenges,
referrals may be made to allied healthcare providers who may work to support psychosocial
adjustment and, thereby, minimize the impact of the disease and treatment. By proactively
offering vulnerable patients support for psychosocial disablement, the confounding nature of
interrelated biopsychosocial symptom clusters may be diminished. Thus, not only does screening
for resilience provide the opportunity for the provision of increased support with psychosocial
adjustment, it also works to optimize the delivery of biologically focused care.
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The results of the present study are viewed to justify screening for resilience in
individuals who have been diagnosed with HNCa, however, it is suggested that compassion
should guide the timing of resilience screening. For instance, at the time of initial diagnosis,
patients may be overwhelmed with emotionally charged information. As such, compassionate
consideration of the timing of resiliency screening may be in the best interest of the patient and
may also ensure an accurate result is obtained from the screen. In light of these considerations, it
suggested that future research be conducted to investigate the efficacy and validity of providing a
resilience measurement instrument, such as the CD-RISC, to the patient’s significant other.
Using a significant other as a proxy to index the resilience of the patient may serve to reduce the
demands on the patient at a potentially intense time of both physical and psychological
challenge.
The clinical implications for minimizing the psychosocial challenges of HNCa may also
lay in potential interventions aimed at fostering and increasing individuals’ resilience. While the
efficacy of potential interventions that nurture resilience has not yet been studied in HNCa
survivorship populations, the virtue of such interventions would be of significance given that
resilience is malleable and amenable to nurturance and training (Tian & Hong, 2014). Through
interventions that foster resilience, patient well-being may be promoted (Loprinzi et al., 2011).
Studies of resilience training interventions in other oncological populations have shown
considerable promise. For instance, Loprinzi et al. (2011) assessed the effect of a resiliency
training program in a sample of individuals previously diagnosed with breast cancer. The
findings of their study demonstrated a significant improvement in resilience, as well as reduced
anxiety and improved overall QoL following the training program. The feasibility and efficacy of
interventions that foster resilience was also demonstrated in a study by Sharpley et al. (2013) in
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which it was found that resilience could be fostered to decrease depression in individuals with
prostate cancer. Ultimately, the screening and identification of individuals who are at a
heightened risk for the development of psychosocial disablement, allows them to be directed
towards interventions before psychosocial morbidity is firmly manifested. In turn, interventions
that foster resilience proactively bolster individuals’ capacity to rebound from any current or
future psychosocial challenges.
Therefore, proactive consideration and enhancement of positive psychosocial factors,
namely resilience, may have a role in clinical practice that is just as critical as minimizing the
negative risk factors (e.g., concerning symptoms, long-term and late effects) faced by HNCa
survivors (Li & Wang, 2016). In light of findings of the present study, it is suggested that
interventions that work to enhance resilience may ultimately augment efforts to reduce the
negative biopsychosocial risk factors associated with HNCa. Therefore, further research should
aim to investigate the efficacy of resilience-enhancing interventions in HNCa survivors and the
potential for such interventions to have the secondary effect of minimizing the biopsychosocial
consequences of HNCa and maximizing QoL. Ultimately, clinically meaningful short- and longterm outcomes may be promoted by interventions that promote and foster resilience in those
individuals identified to be less resilient and, thus, at a heightened risk of developing
psychosocial morbidity. By fostering resilience HNCa survivors QoL may be maximized and the
impact of the disease may be minimized.
Directions for Future Research
The findings of the present study provide an initial foundation from which future research
can build a holistic and comprehensive understanding of resilience and its relationship with QoL
in HNCa survivors. It is recommended that future research explore the trajectory of resilience
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throughout the clinical pathway of HNCa treatment and into the phases of long-term
survivorship. To accomplish this objective, a prospective longitudinal design is suggested to
elucidate how resilience changes over time and relative to certain events that occur throughout
the clinical pathway and survivorship. Furthermore, simultaneous comparison of the trajectory of
QoL may serve to clarify the nature of the relationship between resilience and QoL. It is
recognized that variability may exist given the rapid changes in myriad variables and challenges
from time of diagnosis to completion of treatment and beyond into extended survivorship. By
delineating the course and process of resilience and the potential implications on QoL,
recommendations that guide the timing of proactive interventions pertaining to resilience in
individuals with HNCa may be designed and implemented. For instance, it is recommended that
future research investigate how and when the prophylactic intent of resilience enhancing
interventions may be optimized through insight into the pattern of resilience. Understanding the
trajectory of resilience may serve to predict when the level of resilience may be lowest and, thus,
when individuals may be at a heightened risk for psychosocial disablement and detriments to
QoL. Furthermore, future research that delineates the trajectory of resilience in the specific
context of various subgroups of HNCa, may elicit data relative to potential predictors that are
unique to the HNCa disablement experience and that serve to influence the individual’s capacity
for resilience.
Previous research that has investigated predictors of adult resilience has been limited to
idiosyncratic person-centered factors (e.g., optimism, hardiness) (Bonanno et al., 2007). Thus, it
is recommended that future research seeks to identify potential contextual factors specific to the
adverse circumstances of the survivorship experience of HNCa that may serve as predictors of
adult resilience. Resilience is not borne of adversity but rather, emerges within the context of

108

adverse circumstances. Therefore, understanding the specific HNCa related factors that may
interact with and influence the well-documented developmental factors of resilience that
originate during childhood, may help to guide the targets of HNCa specific resilience enhancing
interventions in adult survivors. Ultimately, given the benevolent influence of resilience on QoL
in cancer survivors in general and HNCa survivors in specific, further research may provide
valuable information that may expand knowledge of the potential impact of resilience on
outcomes.
Conclusions
In summary, resilience was found to be present in the current sample of HNCa survivors.
The identification of resilience in individuals who had completed treatment for HNCa suggests
that positive adaptation is possible following the potentially disabling experience of the disease
and its treatment. The HNCa disablement experience has the potential to exert a profound impact
on survivors’ physical, psychological, and social functioning (Bornbaum et al., 2012). In turn,
profound biopsychosocial challenges associated with HNCa and its treatment have the potential
to reduce one’s QoL. In the context of the HNCa disablement experience, the present study also
identified a relationship between resilience and QoL. As such, resilience may play a central role
in reducing or ameliorating the negative influence of the HNCa disablement experience on QoL.
Due to advancements in treatment efficacy, cancer survival rates are increasing (Giuliani
et al., 2016; Stanton et al., 2015; Wells et al., 2015). As such, there is an increasing number of
individuals who must face the potentially disabling biopsychosocial consequences of HNCa and
diminished QoL. With the rising rate of survivorship comes the need to address the
consequences commonly faced by survivors, or better yet, identify those who are vulnerable to
falling victim to the impact of the biopsychosocial consequences of the disease and its treatment.
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It is suggested that screening for resilience and identifying vulnerable individuals, may present as
a proactive approach that serves to minimize the influence of challenges faced by survivors.
Given the disabling impact of these challenges on QoL, interventions that foster resilience may
facilitate not only the minimization of the impact of the disease, but also the maximization of
QoL. Thus, the importance of resilience in HNCa survivors cannot be understated. Finally, given
the growing number of HNCa survivors who must take up citizenship in the “remission society”
(Frank, 1995, p. 8), there is a great need to proactively address the complex issues faced by those
who are no longer “sick”, but remain plagued by the consequences of their illness. Ultimately,
resilience may guide citizens of the remission society away from the kingdom of the sick and aid
in the renewal of their passport to the kingdom of the well.
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APPENDIX C

An Exploration of Resilience in Individuals Treated for Head and Neck Cancer
Rehabilitation Sciences
Western University
Letter of Information
Principal Investigators: Philip C. Doyle, Ph.D. & Chelsea MacDonald, B.H.Sc.
Introduction
You are being invited to participate in a research study exploring resilience and quality of life
among individuals who have completed treatment for head and neck cancer. The term resilience
refers to how individuals respond to challenges in their lives and ultimately how they bounce
back in the face of such challenges. Resilience may define how individuals reestablish a “sense
of balance” in their daily living. Your participation is requested because you have been
diagnosed with head and neck cancer, and are between one month and five years beyond the
completion of treatment. This study seeks to understand how resilience may have influenced
your quality of life in the context of your experience of surviving head and neck cancer.
The purpose of this letter is to provide you with the information you require to make an informed
decision regarding your participation in this research study. This letter contains information to
aid in your decision of whether or not to participate in this research. It is important that you
understand the rationale for why this study is being conducted and what your participation will
involve. Please take your time to read this letter and feel free to ask any questions to ensure your
understanding is complete. You will be given a copy of this letter to keep for your records.
Purpose of Study
The purpose of this research study is to investigate the influence of resilience on the quality of
life of individuals who have completed treatment for head and neck cancer. This study is being
conducted to explore the potential for resilience to play a role in buffering the influence of the
adverse experience of head and neck cancer and its treatment on your quality of life. The primary
aim of the present study centres on the identification and description of resilience in individuals
who have completed treatment for head and neck cancer. The identification of resilience may
initiate acknowledgement of its value in acting as a potential protective factor that may reduce
the impact of head and neck cancer on one’s quality of life.
This study represents a portion of a master’s thesis project for one of the investigators (C.M.).
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Activities of Participation
If you agree to participate in this research, you will receive a package of materials that will allow
for the collection of data to investigate resilience and its potential role in reducing the negative
effect of head and neck cancer on quality of life. Enclosed in your package will be a
demographic information inquiry form, and three questionnaires pertaining to resilience and
quality of life in relation to your cancer experience. The questionnaires you will be asked to
complete in your package include the Connor-Davidson Resilience Scale (CD-RISC) to gather
data pertaining to resilience, the European Organization for the Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and the European Organization for
Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-H&N35) to
gather information regarding your quality of life. The completion of these materials is estimated
to take approximately 20 minutes. You may complete the package of materials at the time you
consent to participate, or take it home and return it by mail at a later date. A prepaid and preaddressed envelope for the return of the package of materials will be provided if you choose to
complete the study package off site.
Please note that you will not be compensated for your participation in this research study.
Inclusion and Exclusion Criteria
Inclusion Criteria
Your participation in this study is based on your diagnosis of head and neck cancer, as well as
your completion of any type of treatment. Participation is limited to individuals who are a
minimum of one month, but no more than five years beyond the completion of treatment. You
must be between the ages of 25 and 85. Participants must display adequate English proficiency
required for informed consent to be obtained and the completion of the package of study
materials.
Exclusion Criteria
Exclusion from participation in this study may be based on an individual’s previous diagnosis of
another cancer regardless of its location. Individuals that have been diagnosed and treated for
skin cancer in the head and neck region will not be permitted to participate. Cancer treatment
that is ongoing will also exclude individuals from participation.
Possible Benefits and Risks Involved in Participation
Possible Benefits
You are unlikely to directly benefit as a result of your participation in this research study.
However, a better understanding and awareness of factors that may affect resiliency and quality
of life may be gained from your participation. At a societal level, data collected through this
study may provide health care practitioners with information regarding the value of screening for
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resilience in order to identify individuals with low levels of resilience and thus, higher
vulnerability to the influence of negative consequences associated with head and neck cancer.
Possible Risks
There are no foreseeable risks or discomforts associated with your participation in this research
study. However, you will be asked to complete questionnaires that may delve into sensitive
topics pertaining to your resilience and quality of life. Consequently, you may experience
negative emotions. If this occurs, it is requested that you contact your physician, or a member of
the research team should you require help managing these negative emotions. Additionally, a
contact list for local psychological support services and organizations that offer support to
individuals that have experienced head and neck cancer is included in the package of study
materials.
Voluntary Participation
Your participation in this research study is entirely voluntary. You may refuse to participate,
refuse to answer any questions or withdraw from the study at any time with no negative
consequences. You do not waive any legal rights by signing the consent form. Making the
decision not to participate in this study will have no impact on your future health care.
Confidentiality
All data collected in this study will remain confidential. Personally identifying information will
not be retained. All data will be kept in a secure locked location at Western University. If the
results of this study are published, no information that could disclose your identity will be used.
Representatives of The University of Western Ontario Health Sciences Research Ethics Board
may contact you or require access to your study related records to monitor the conduct of the
research.
Contacts for Further Questions
If you require further information regarding this research study or additional questions arise in
relation to your participation in this study, please feel free to contact:
Philip C. Doyle, Ph.D. or Chelsea MacDonald, B.H.Sc.
Laboratory for Well-Being and Quality of Life in Oncology
Health and Rehabilitation Sciences
Elborn College, Western University
London, Ontario N6G 1H1
519-661-2111 ext. 88942
pdoyle@uwo.ca
cmacdo96@uwo.ca

130

If you have any questions about the conduct of this study or your rights as a research subject, you
may contact:
Office of Human Research Ethics
Research Western
Room 5150 Support Services Building, 1393
Western Road
London, Ontario, Canada, N6G1G9
Tel: RDS: 519-661-2161 | Research Ethics: 519-661-3036
res-serv@uwo.ca
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Rehabilitation Sciences
Western University

Letter of Consent

Study Title: An Exploration of Resilience in Individuals Treated for Head and Neck Cancer

Principal Investigators: Philip C. Doyle, Ph.D. & Chelsea MacDonald, B.H.Sc.

I have read the Letter of Information, have had the nature of the study explained to me, and I
agree to participate. All questions have been answered to my satisfaction.

________________________________________
Participant’s Name (Printed)

_________________________________________
Participant’s Signature

_________________________________________
Signature of Person Obtaining Consent

__________________
Date (dd/mm/yyyy)

__________________
Date (dd/mm/yyyy)
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Demographic Information Survey
Title: An Exploration of Resilience in Individuals Treated for Head and Neck Cancer
Study Investigators: Philip C. Doyle, Ph.D. & Chelsea MacDonald, B.H.Sc.
Please read the following questions carefully and provide answers as accurately as possible. For multiple
choice options, please circle all choices that apply to you. If no suitable options exist, please use the
space provided to explain. Also, if there is any additional information that you feel is important to report
please use the back of these pages to include it.
Sex: M / F / Other
Year of Birth: ___________ Month of Birth: ___________
Number of months since your diagnosis: _____________
Number of months since treatment completion: _____________
Site of Cancer:

a) Oral cavity (e.g., lip, tongue, cheek, tonsil, etc.)
b) Larynx (voice box)
c) Throat (e.g., pharynx, hypopharynx, oropharynx)
d) Thyroid
e) Sinuses/Paranasal sinuses
f) Other
If “other”, please specify:
____________________________________________________________________
Method of Treatment:

a) Surgery
b) Radiation therapy
c) Chemotherapy
d) Chemoradiation therapy
e) Other

If “other”, please specify:
____________________________________________________________________
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Marital Status (circle one):

a) Married
b) Separated
c) Divorced
d) Widowed
e) Common-law
f) Engaged
g) Single
h) Other
If “other”, please specify:
____________________________________________________________________
Occupational Status:

a) Currently working – full-time
b) Currently working – part-time
c) Volunteer
d) Retired
e) Other
If “other”, please specify:
____________________________________________________________________
Highest Level of Education Achieved:

a) Completed High school
b) Completed College
c) Undergraduate University degree
d) Post-graduate University degree
e) Other
If “other”, please specify:
____________________________________________________________________
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Household income (optional):
(a)
(b)
(c)
(d)
(e)
(f)
(g)

Less than $25, 000
$25, 000 - $40, 000
$40, 001 - $55, 000
$55, 001 - $70, 000
$70, 001 - $85, 000
Greater than $85, 000
Would prefer not to say

Please feel free to include any additional information that you feel is important specific to this project in
the space provided below or on the opposite side of this document. Thank you.
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

134

APPENDIX E

135

APPENDIX F

136

137

APPENDIX G

138

139

APPENDIX H
Scoring Procedure for EORTC QLQ-C30 and EORTC QLQ-H&N35
Summary of scoring procedure:
1. Estimate the average of the items that contribute to the scale; this is the raw score.
2. Use a linear transformation to standardize the raw score, so that scores range from 0 to
100; this is the scale score.
Example:
If items I1, I2, … In, are included in a scale, the scoring procedure is as follows:
1. Raw score calculation
RawScore = RS = (I1 + I2 + …+ In) / n
2. Linear transformation
For Functional Scales: S = {1 −

𝑅𝑆−1
𝑟𝑎𝑛𝑔𝑒

} x 100
(𝑅𝑆−1)

Symptom Scales/Single Item Measures: S = { 𝑟𝑎𝑛𝑔𝑒 } x 100
(𝑅𝑆−1)

Global Health Status/QoL: S = { 𝑟𝑎𝑛𝑔𝑒 } x 100
Where range is the difference between the maximum and minimum RS values.

Adapted from: Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., &
Bottomley, A. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: European
Organisation for Research and Treatment of Cancer.
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